1
|
Li Z, Tong G, Peng X, Wang S. Circ_0000370 Plays an Oncogenic Role in Colorectal Cancer by Regulating the miR-502-5p/SIRT1 Axis. Biochem Genet 2024; 62:1231-1247. [PMID: 37561331 DOI: 10.1007/s10528-023-10468-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 07/24/2023] [Indexed: 08/11/2023]
Abstract
The importance of circular RNA has been reported in cancer development. However, the role and mechanism of circ_0000370 in CRC progression are still unclear. Quantitative real-time PCR and Western blot assay were performed to measure RNA and protein expression. Cell proliferation was assessed by cell colony formation assay and 5-Ethynyl-2'-deoxyuridine assay. Flow cytometry was used to measure cell apoptosis. Cell migration and invasion were detected by transwell assay. The intermolecular target relations between miR-502-5p and circ_0000370 or SIRT1 were confirmed by dual-luciferase reporter assay and RNA immunoprecipitation assay. A xenograft tumor model was established to examine the role of circ_0000370 in tumor growth in vivo. As compared with controls, the expression of circ_0000370 was upregulated in CRC tissues and cells. Circ_0000370 depletion inhibited CRC cell proliferation, migration and invasion but induced cell apoptosis. Meanwhile, circ_0000370 depletion restrained tumor growth in vivo. In addition, miR-502-5p inhibitor partly reverted the impacts of circ_0000370 knockdown on CRC cells. Moreover, miR-502-5p mimic-caused effects on cell phenotypes were attenuated by SIRT1 overexpression. Circ_0000370 induced the proliferation and metastasis of CRC cells by sponging miR-502-5p and enhancing SIRT1 expression, which provided a possible target for CRC treatment.
Collapse
Affiliation(s)
- Zhu Li
- Department of Oncology, Peking University Shenzhen Hospital, 1120 Lianhua Road, Futian District, Shenzhen, 518000, Guangdong, China
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, 1120 Lianhua Road, Futian District, Shenzhen, 518000, Guangdong, China
| | - Xiaodan Peng
- Department of Oncology, Peking University Shenzhen Hospital, 1120 Lianhua Road, Futian District, Shenzhen, 518000, Guangdong, China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, 1120 Lianhua Road, Futian District, Shenzhen, 518000, Guangdong, China.
| |
Collapse
|
2
|
Li C, Cheng B, Yang X, Tong G, Wang F, Li M, Wang X, Wang S. Corrigendum to "SOX8 promotes tumor growth and metastasis through FZD6-dependent Wnt/β-catenin signaling in colorectal carcinoma" [Heliyon 9(12) (December 2023) e22586]. Heliyon 2024; 10:e23966. [PMID: 38332868 PMCID: PMC10851285 DOI: 10.1016/j.heliyon.2023.e23966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Accepted: 12/21/2023] [Indexed: 02/10/2024] Open
Abstract
[This corrects the article DOI: 10.1016/j.heliyon.2023.e22586.].
Collapse
Affiliation(s)
| | | | - Xiaodong Yang
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Gangling Tong
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Fen Wang
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Mengqing Li
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Xiangyu Wang
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Shubin Wang
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| |
Collapse
|
3
|
Li C, Cheng B, Yang X, Tong G, Wang F, Li M, Wang X, Wang S. SOX8 promotes tumor growth and metastasis through FZD6-dependent Wnt/β-catenin signaling in colorectal carcinoma. Heliyon 2023; 9:e22586. [PMID: 38046159 PMCID: PMC10686890 DOI: 10.1016/j.heliyon.2023.e22586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 11/05/2023] [Accepted: 11/15/2023] [Indexed: 12/05/2023] Open
Abstract
SOX8 plays an important role in several physiological processes. Its expression is negatively associated with overall survival in patients with colorectal carcinoma (CRC), suggesting SOX8 is a potential prognostic factor for this disease. However, the role of SOX8 in CRC remains largely unknown. In this study, our data showed that SOX8 expression was upregulated in CRC cell lines and tumor tissues. Stable knockdown of SOX8 in CRC cell lines dramatically reduced cell proliferation, migration, and invasion. Furthermore, the knockdown of SOX8 decreased the phospho-GSK3β level and suppressed Frizzled-6 (FZD6) transcription; restoration of FZD6 expression partially abolished the effect of SOX8 on Wnt/β-catenin signaling and promote CRC cell proliferation. In conclusion, our findings suggested that SOX8 served as an oncogene in CRC through the activation of FZD6-dependent Wnt/β-catenin signaling.
Collapse
Affiliation(s)
- Chen Li
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Boran Cheng
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Xiaodong Yang
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Gangling Tong
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Fen Wang
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Mengqing Li
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Xiangyu Wang
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| | - Shubin Wang
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China
| |
Collapse
|
4
|
Wu X, Zhou F, Cheng B, Tong G, Chen M, He L, Li Z, Yu S, Wang S, Lin L. Immune activity score to assess the prognosis, immunotherapy and chemotherapy response in gastric cancer and experimental validation. PeerJ 2023; 11:e16317. [PMID: 38025711 PMCID: PMC10655707 DOI: 10.7717/peerj.16317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 09/28/2023] [Indexed: 12/01/2023] Open
Abstract
Background Gastric cancer (GC) is an extremely heterogeneous malignancy with a complex tumor microenvironment (TME) that contributes to unsatisfactory prognosis. Methods The overall activity score for assessing the immune activity of GC patients was developed based on cancer immune cycle activity index in the Tracking Tumor Immunophenotype (TIP). Genes potentially affected by the overall activity score were screened using weighted gene co-expression network analysis (WGCNA). Based on the expression profile data of GC in The Cancer Genome Atlas (TCGA) database, COX analysis was applied to create an immune activity score (IAS). Differences in TME activity in the IAS groups were analyzed. We also evaluated the value of IAS in estimating immunotherapy and chemotherapy response based on immunotherapy cohort. Gene expression in IAS model and cell viability were determined by real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) and Cell Counting Kit-8 (CCK-8) assay, respectively. Results WGCAN analysis screened 629 overall activity score-related genes, which were mainly associated with T cell response and B cell response. COX analysis identified AKAP5, CTLA4, LRRC8C, AOAH-IT1, NPC2, RGS1 and SLC2A3 as critical genes affecting the prognosis of GC, based on which the IAS was developed. Further RT-qPCR analysis data showed that the expression of AKAP5 and CTLA4 was downregulated, while that of LRRC8C, AOAH-IT1, NPC2, RGS1 and SLC2A3 was significantly elevated in GC cell lines. Inhibition of AKAP5 increased cell viability but siAOAH-IT1 promoted viability of GC cells. IAS demonstrated excellent robustness in predicting immunotherapy outcome and GC prognosis, with low-IAS patients having better prognosis and immunotherapy. In addition, resistance to Erlotinib, Rapamycin, MG-132, Cyclopamine, AZ628, and Sorafenib was reduced in patients with low IAS. Conclusion IAS was a reliable prognostic indicator. For GC patients, IAS showed excellent robustness in predicting GC prognosis, immune activity status, immunotherapy response, and chemotherapeutic drug resistance. Our study provided novel insights into the prognostic assessment in GC.
Collapse
Affiliation(s)
- Xuan Wu
- Department of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, China
- Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen, China
- Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Fengrui Zhou
- Department of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, China
- Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen, China
- Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Boran Cheng
- Department of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, China
- Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen, China
- Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Gangling Tong
- Department of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, China
- Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen, China
- Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Minhua Chen
- Community Healthcare Center of Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
| | - Lirui He
- Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, Shenzhen, China
| | - Zhu Li
- Department of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, China
- Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen, China
- Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Shaokang Yu
- Department of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, China
- Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen, China
- Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Shubin Wang
- Department of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, China
- Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen, China
- Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Liping Lin
- Department of Oncology, Panyu Central Hospital, Cancer Institute of Panyu, Guangzhou, China
| |
Collapse
|
5
|
Yuan W, Zhou X, Cai Z, Qiu J, Li X, Tong G. Risk Factors of Gastrointestinal Perforation with a Poor Prognosis. Int J Gen Med 2023; 16:4637-4647. [PMID: 37868819 PMCID: PMC10588753 DOI: 10.2147/ijgm.s426676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 10/09/2023] [Indexed: 10/24/2023] Open
Abstract
Background Despite medical progress, mortality from gastrointestinal perforation was relatively high. Our study's objective was to identify risk factors associated with a poor prognosis for gastrointestinal perforation. Methods Patients diagnosed with gastrointestinal perforation at the Longchuan County People's Hospital between January 2019 and February 2022 were the subject of a retrospective analysis of their laboratory data. Patients were grouped based on length of hospital stay, septic shock, and mortality. Results A total of 240 patients participated in our study. Using univariate and multivariate analysis, we identified several risk factors for gastrointestinal perforation associated with a dismal prognosis. Lower digestive tract perforation (OR=2.418, 95% CI 1.119-5.227, P=0.025), low total protein (OR=0.934, 95% CI 0.879-0.992, P=0.026) and low hemoglobin (OR=0.985, 95% CI 0.971-0.999, P=0.039) were linked to a longer length of stay, especially hemoglobin (OR=0.978, 95% CI 0.966-0.991, P=0.001) in upper digestive tract. High ratio of neutrophils to lymphocytes (NLR) (OR=1.043, 95% CI 1.012-1.076, P=0.007), high lymphocyte-to-monocyte ratio (LMR) (OR=2.158, 95% CI 1.495-3.115, P<0.001) and low prognostic nutrition index (PNI) (OR=0.814, 95% CI 0.751-0.833, P<0.001) predicted septic shock. In upper digestive tract, PLR (OR=1.001, 95% CI 1.000-1.002, P=0.067), LMR (OR=2.160, 95% CI 1.440-3.240, P<0.001) and PNI (OR=0.843, 95% CI 0.767-0.926, P<0.001) were risk factors for septic shock, and total protein (OR=0.796, 95% CI 0.686-0.923, P=0.003) was a risk factor for septic shock in lower digestive tract. High NLR (OR=1.056, 95% CI 1.019-1.093, P=0.003), high LMR (OR=1.760, 95% CI 1.177-2.632, P=0.006) and low PNI (OR=0.832, 95% CI 0.754-0.918, P<0.001) were the risk factors of mortality. In subgroup analysis of perforation site, albumin (OR=0.820, 95% CI 0.719-0.934, P=0.003) and LMR (OR=1.506, 95% CI 1.069-2.123, P=0.019) were risk factors for mortality in upper digestive tract and PNI (OR=0.636, 95% CI 0.445-0.908, P=0.013) was a risk factor for mortality in lower digestive tract. Conclusion Our research found that the perforation site, total protein, albumin, hemoglobin, NLR, LMR, PLR and PNI were risk factors for gastrointestinal perforation with a poor prognosis.
Collapse
Affiliation(s)
- Wenqing Yuan
- Department of Gastrointestinal Surgery, Longchuan County People’s Hospital, Heyuan, 517300, People’s Republic of China
| | - Xiaozhuan Zhou
- Department of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, 518036, People’s Republic of China
| | - Zhigao Cai
- Department of Gastrointestinal Surgery, Longchuan County People’s Hospital, Heyuan, 517300, People’s Republic of China
| | - Junyu Qiu
- Department of Gastrointestinal Surgery, Longchuan County People’s Hospital, Heyuan, 517300, People’s Republic of China
| | - Xi Li
- Department of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, 518036, People’s Republic of China
| | - Gangling Tong
- Department of Gastrointestinal Surgery, Longchuan County People’s Hospital, Heyuan, 517300, People’s Republic of China
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, China and Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, 518036, People’s Republic of China
| |
Collapse
|
6
|
Li Z, Tong G, Peng X, Wang S. Circ_0005785 Silencing Constrains the Functional Properties of Colorectal Cancer Cells Depending on miR-7-5p/DNMT3A Axis. Biochem Genet 2023:10.1007/s10528-023-10522-6. [PMID: 37730966 DOI: 10.1007/s10528-023-10522-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Accepted: 09/07/2023] [Indexed: 09/22/2023]
Abstract
Circular RNAs (circRNAs) closely related to the progression of colorectal cancer (CRC). Nevertheless, the study of circ_0005785 in CRC has not been reported. In this test, we aimed to investigate the mechanisms of circ_0005785 in CRC development. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot were employed to reveal the expression of genes and proteins. Cell Counting Kit-8 (CCK-8) assay, 5-ethynyl-2'-deoxyuridine (EdU) assay, flow cytometry analysis, transwell assay and tube formation experiment were implemented to examine cell growth, apoptosis, invasion and angiogenesis. The relationships among circ_0005785, miR-7-5p and DNA methyltransferase 3 A (DNMT3A) were verified by dual-luciferase reporter assay. Xenograft mouse model was built to evaluate the impacts of circ_0005785 deficiency on CRC growth in vivo. We found that circ_0005785 was increased in CRC patients and cell lines. Circ_0005785 downregulation retarded cell proliferation, invasion, angiogenesis whereas expedited apoptosis in CRC cells. Mechanistically, circ_0005785 could sponge miR-7-5p and the suppressive treads of circ_0005785 in CRC development was attenuated by miR-7-5p down-regulation. DNMT3A was targeted by miR-7-5p and miR-7-5p overexpression constrained cell malignant behaviors, but the addition of DNMT3A counteracted the effects. Additionally, circ_0005785 inhibition hindered the tumor growth in vivo. In conclusion, circ_0005785 aggravated the CRC progression by increasing the level of DNMT3A via adsorbing miR-7-5p.
Collapse
Affiliation(s)
- Zhu Li
- Department of oncology, Peking Universtity Shenzhen Hospital, 1120 Lianhua Road, Futian District, Shenzhen, Guangdong Province, 518000, China
| | - Gangling Tong
- Department of oncology, Peking Universtity Shenzhen Hospital, 1120 Lianhua Road, Futian District, Shenzhen, Guangdong Province, 518000, China
| | - Xiaodan Peng
- Department of oncology, Peking Universtity Shenzhen Hospital, 1120 Lianhua Road, Futian District, Shenzhen, Guangdong Province, 518000, China
| | - Shubin Wang
- Department of oncology, Peking Universtity Shenzhen Hospital, 1120 Lianhua Road, Futian District, Shenzhen, Guangdong Province, 518000, China.
| |
Collapse
|
7
|
Tong G, Zhu M, Chen Y, Wang S, Cheng B, Wang S, Liao W. Intratumoral CD8+ T cells as a potential positive predictor of chemoimmunotherapy response in PD-L1-negative advanced gastric cancer patients: a retrospective cohort study. J Gastrointest Oncol 2022; 13:1668-1678. [PMID: 36092315 PMCID: PMC9459198 DOI: 10.21037/jgo-22-644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 07/29/2022] [Indexed: 11/16/2022] Open
Abstract
Background Previous studies have shown that PD-L1-positive advanced gastric cancer (GC) patients could achieve clinical benefit after receiving immune checkpoint inhibitors (ICI) in initial or subsequent therapy. A number of prospective studies such as Keynote-158 have demonstrated that PD-L1-negative patients who tested as microsatellite instability-high (MSI-H) or tumor mutational burden-high (TMB-H) can benefit from ICIs. In the search for more biomarker for immunotherapy, some studies showed that patients with a specific characteristic to tumor microenvironment (TME) were associated with better prognosis. This study aimed to explore the association between the TME and immunotherapy in PD-L1 negative GC patients. Methods This study was a retrospective cohort study. Twenty-six CPS PD-L1 negative stage IV advanced GC patients treated with chemoimmunotherapy in Shenzhen Hospital of Peking University were retrospectively enrolled according to the inclusion criteria. Their clinical characteristics were assessed and recorded by independent clinicians. Follow-up data was conducted through the Internet or visit. Respond to treatment was evaluated by RECIST 1.1. The primary outcome was progression-free survival (PFS). The level of tumor-infiltrating lymphocytes (TILs) was measured by multiplex immunofluorescence (mIF) among these patients. Cox proportional hazards analysis was performed to analyzed the correlation between PFS and clinical characteristics including TILs. Results Among 26 patients, 5 patients (19.2%) were on complete response (CR) and 9 patients (34.6%) were in partial response (PR), while 7 patients (26.9%) experienced stable disease (SD). Intratumoral CD8+ T cells were obviously increased in CPS PD-L1 negative patients who responded to chemoimmunotherapy, compared with patients who did not respond (P=0.011). And higher level of CD8+ TILs was demonstrated to associate with better PFS in CPS PD-L1-negative patients treated with chemoimmunotherapy (HR =23.70, 95% CI: 1.15–488.30, P=0.04). Conclusions Intratumoral CD8+ TILs may be a potential positive predictive factor of clinical response for chemoimmunotherapy in PD-L1-negative advanced GC. However, the results need to be further confirmed in a cohort with more subjects due to a limited sample sizes in present study.
Collapse
Affiliation(s)
- Gangling Tong
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen, China
| | - Meiqin Zhu
- Department of Medical Oncology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China
| | - Yaoxu Chen
- The Medical Department, 3D Medicines Inc., Shanghai, China
| | - Shubo Wang
- The Medical Department, 3D Medicines Inc., Shanghai, China
| | - Boran Cheng
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen, China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen, China
| | - Wangjun Liao
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| |
Collapse
|
8
|
Zhu Y, Lu Y, Zhou C, Tong G, Gao M, Zhan Y, Wang Y, Liang R, Li Y, Gao T, Wang L, Zhang M, Cheng J, Gong J, Wang J, Zhang W, Qi J, Cui M, Zhu L, Xiao F, Zhu L, Xu Y, Zheng Z, Zhou Z, Cheng Z, Hong P. Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines. Med (N Y) 2022; 3:568-578.e3. [PMID: 35679856 PMCID: PMC9181311 DOI: 10.1016/j.medj.2022.05.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 04/13/2022] [Accepted: 05/11/2022] [Indexed: 12/21/2022]
Abstract
Background Emerging evidence suggests heterologous prime-boost COVID-19 vaccination as a superior strategy than homologous schedules. Animal experiments and clinical observations have shown enhanced antibody response against influenza variants after heterologous vaccination; however, whether the inoculation order of COVID-19 vaccines in a prime-boost schedule affects antibody response against SARS-CoV-2 variants is not clear. Methods We conducted immunological analyses in a cohort of health care workers (n = 486) recently vaccinated by three types of inactivated COVID-19 vaccines under homologous or heterologous prime-boost schedules. Antibody response against ancestral SARS-CoV-2 (Wuhan-Hu-1) was assessed by total antibody measurements, surrogate virus neutralization tests, and pseudovirus neutralization assays (PNA). Furthermore, serum neutralization activity against SARS-CoV-2 variants of concern was also measured by PNA. Findings We observed strongest serum neutralization activity against the widely circulating SARS-CoV-2 variant B.1.617.2 among recipients of heterologous BBIBP-CorV/CoronaVac and WIBP-CorV/CoronaVac. In contrast, recipients of CoronaVac/BBIBP-CorV and CoronaVac/WIBP-CorV showed significantly lower B.1.617.2 neutralization titers than recipients of reverse schedules. Laboratory tests revealed that neutralizing activity against common variants but not the ancestral SARS-CoV-2 was associated with the inoculation order of heterologous prime-boost vaccines. Multivariable regression analyses confirmed this association after adjusting for known confounders. Conclusions Our data provide clinical evidence of inoculation order-dependent expansion of neutralizing breadth against SARS-CoV-2 in recipients of heterologous prime-boost vaccination and call for further studies into its underlying mechanism. Funding National Key R&D Program of China, National Development and Re-form Commission of China, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission, and US Department of Veterans Affairs. Many people around the world have received different types of COVID-19 vaccines in their two-dose vaccination schedules for various reasons. However, it is not clear whether the inoculation order of such heterologous vaccines was associated with subsequent immune responses. Here, an international team of physicians and scientists from China and the United States studied a cohort of healthcare workers who were among the earliest recipients of heterologous COVID-19 vaccination. The authors found that the inoculation order of heterologous vaccines was associated with the capability of neutralizing SARS-CoV-2 variants but not the original strain that the vaccines were based on. The results suggested that using heterologous booster vaccines with high potency could be a cost-efficient way to elicit protective immunity against future variants.
Collapse
Affiliation(s)
- Yufang Zhu
- Laboratory of Clinical Immunology, Division of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Yingying Lu
- Center for Kidney Diseases, Department of Nephrology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China; Department of Biomedical Science, Shenzhen Research Institute, City University of Hong Kong, Kowloon Tong, Hong Kong, China
| | - Caili Zhou
- Laboratory of Clinical Immunology, Division of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
| | - Manman Gao
- Innovation Platform of Regeneration and Repair of Spinal Cord and Nerve Injury, Department of Orthopedic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China; Institute of Translational Medicine, Department of Sport Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
| | - Yan Zhan
- Department of Rehabilitation Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Yan Wang
- Department of Obstetrics and Gynecology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China
| | - Ran Liang
- Laboratory of Clinical Immunology, Division of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Yawei Li
- Laboratory of Clinical Immunology, Division of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Tianjiao Gao
- Laboratory of Clinical Immunology, Division of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Li Wang
- Laboratory of Clinical Immunology, Division of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Muyun Zhang
- Laboratory of Clinical Immunology, Division of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Jin Cheng
- Department of Research Affairs, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Jun Gong
- Department of Orthopedic Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Jimin Wang
- Department of Traditional Chinese Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China
| | - Wei Zhang
- Department of Research Affairs, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China
| | - Junhua Qi
- Department of Laboratory Medicine, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China
| | - Miao Cui
- Department of Pathology, Mount Sinai St. Luke's Roosevelt Hospital Center, New York, NY 10025, USA
| | - Longchao Zhu
- Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China
| | | | - Linyu Zhu
- Department of Dermatology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China
| | - Yunsheng Xu
- Department of Research Affairs, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China; Department of Dermatology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China
| | - Zhihua Zheng
- Center for Kidney Diseases, Department of Nephrology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China
| | - Zhiyu Zhou
- Innovation Platform of Regeneration and Repair of Spinal Cord and Nerve Injury, Department of Orthopedic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
| | - Zhengjiang Cheng
- Laboratory of Clinical Immunology, Division of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.
| | - Peng Hong
- Center for Kidney Diseases, Department of Nephrology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China; Division of Research and Development, US Department of Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY 11209, USA; Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, NY 11203, USA.
| |
Collapse
|
9
|
Tong G, Zhu M, Chen Y, Wang S, Cheng B, Wang S, Liao W. Intratumoral CD8+ t cell as a potential positive predictor for treatment of chemo-immunotherapy in PD-L1 negative advanced gastric cancer patients. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e16029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16029 Background: It was demonstrated that CPS PDL1 positive patients of advanced gastric cancer (GC) could benefit from specific immune checkpoint inhibitors (ICI) for first-line, and second-line or subsequent therapy. However, whether the application of ICI could lead to better clinical outcome in advanced GC patients who were negative for PDL1 remains further explore. Some studies showed that patients with specific tumor immune microenvironment (TME) are more sensitive to immunotherapy. Therefore, TME may be a potential positive predictor for PDL1 negative patients treated with immunotherapy. Methods: We retrospectively enrolled 26 advanced GC patients who were treated by chemoimmunotherapy in Shenzhen Hospital of Peking University and evaluated for clinical characteristics. Peritumoral and intratumoral Tumour-infiltrating lymphocytes (TIL) were detected by mIHC (multiplex immunofluorescence) among these patients. The correlation between PFS and clinical characteristics including TIL was analyzed by univariate survival analysis and multivariate Cox proportional hazards analysis. Results: In 26 patients, 5 patients (19.2%) experienced complete response (CR), 9 patients (34.6%) experienced partial response (PR), while 7 patients (26.9%) experienced stable disease (SD). Compared with non-responders, higher intratumoral infiltrating CD8+ T cells instead of other subtypes were detected in CPS PDL1 negative Patients who respond to chemoimmunotherapy. Further analysis revealed that CD8+ TIL was a predictive biomarker for PFS to chemo-immunotherapy in CPS PDL1 negative patients. Conclusions: For CPS PDL1 negative advanced GC patients, intratumoral CD8+ TIL may be a potential positive predictor for treatment of chemo-immunotherapy.
Collapse
Affiliation(s)
- Gangling Tong
- Department of Medical Oncology, Peking Univeristy Shenzhen Hospital, Shenzhen, China
| | - Meiqin Zhu
- Department of Medical Oncology, Shenzhen People’s Hospital, Shenzhen, China
| | - Yaoxu Chen
- The Medical Department, 3D Medicines Inc., Shanghai, China
| | - Shubo Wang
- The Medical Department, 3D Medicines Inc., Shanghai, China
| | - Boran Cheng
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Wangjun Liao
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| |
Collapse
|
10
|
Tong G, Chen B, Zhang M, Wang T, Wu X, Yan Y, Wang S, Li S. Treatment efficacy and prognosis analysis in locally advanced or metastatic colorectal cancer patients with hydronephrosis. Mol Clin Oncol 2022; 16:106. [PMID: 35620214 PMCID: PMC9112401 DOI: 10.3892/mco.2022.2539] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Accepted: 04/01/2022] [Indexed: 02/05/2023] Open
Abstract
The effect of hydronephrosis, a common complication of metastatic colorectal cancer (CRC), on the treatment outcome and prognosis of locally advanced or metastatic CRC remains to be elucidated. The present study investigated the clinical characteristics, outcomes, and prognoses of patients with locally advanced or metastatic colorectal cancer (CRC) with hydronephrosis. Clinical data of patients with locally advanced or metastatic CRC who were attending Peking University Shenzhen Hospital and Shenzhen Cancer Hospital between January 2016 and December 2020 were retrospectively collected. A total of 52 patients with hydronephrosis based on CT or MRI findings were selected, and their clinical characteristics, treatment outcomes, and survival times were analyzed. Of the 52 patients, 33 were male (63.5%), and the median age was 49 years (range, 31-76 years). A total of 15 (28.8%) patients with CRC had synchronous hydronephrosis and the remaining 37 patients had metachronous hydronephrosis. Ureters were either compressed by peritoneal or abdominal cavity metastatic lymph nodes in 34 cases (65.4%) or by direct tumor invasion in 18 cases (34.6%). However, objective response rate (ORR) was higher in the group in which ureters were compressed by peritoneal or abdominal cavity metastatic lymph nodes; ORR, disease control rate and median progression-free survival (PFS) between the two groups were not statistically different. (P>0.05). The median survival period was only 27.0 months (95% CI, 20.549-33.451) in patients complicated with malignant hydronephrosis. Univariate and multivariate analyses showed that CA19-9 might be a prognostic factor for locally advanced and metastatic CRC patients with hydronephrosis. Metachronous metastatic CRC has a high incidence rate of complicated hydronephrosis. Targeted drugs in combination with chemotherapy improve the treatment efficacy and prognosis of patients. Notably, the present study found that CA19-9 level might be a prognostic factor in CRC patients with hydronephrosis.
Collapse
Affiliation(s)
- Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
| | - Boran Chen
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
| | - Mingying Zhang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
- Shantou University Medical College, Shantou, Guangdong 515041, P.R. China
| | - Tianyu Wang
- Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China
| | - Xuan Wu
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
| | - Yuye Yan
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
| | - Shuluan Li
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China
| |
Collapse
|
11
|
Rolfs N, Tong G, Lücht J, Wowro S, Schmitt KR. Targeted Temperature Management Protects Microglia from Ischemia/Reperfusion-Induced Necrosis and Attenuates the Release of Mediators of Sterile Inflammation. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1743011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- N. Rolfs
- Deutsches Herzzentrum Berlin, Berlin, Deutschland
| | - G. Tong
- Department of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Deutschland
| | - J. Lücht
- Department of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Deutschland
| | - S. Wowro
- Deutsches Herzzentrum Berlin, Berlin, Deutschland
| | - K. R.L. Schmitt
- Department of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Deutschland
| |
Collapse
|
12
|
Li S, Wang T, Lai W, Zhang M, Cheng B, Wang S, Tong G. Prognostic impact of sarcopenia on immune-related adverse events in malignancies received immune checkpoint inhibitors: a systematic review and meta-analysis. Transl Cancer Res 2021; 10:5150-5158. [PMID: 35116365 PMCID: PMC8797877 DOI: 10.21037/tcr-21-1470] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2021] [Accepted: 11/12/2021] [Indexed: 02/05/2023]
Abstract
BACKGROUND Whether sarcopenia has an impact on immune-related adverse events (irAEs) in patients with malignant neoplasms receiving immune checkpoint inhibitors (ICIs) is not consistent. This study aimed to evaluate the impact of sarcopenia on all grades of irAEs. METHODS PubMed, Embase, and Cochrane Library databases were systematically searched for related studies up to May 2021. Eligible studies were included according to the PICOS criteria. The risk of bias of the included studies was assessed according to the Newcastle-Ottawa Scale (NOS). The odds ratio (OR), corresponding to the 95% confidence interval (CI) of all grades of irAEs, was collected and analyzed, and a further subgroup analysis of serious adverse events was conducted. All analyses were conducted using the RevMan 5.4 software downloaded from the Cochrane website. The heterogeneity and sensitivity of the study were assessed. RESULTS Of the 135 references identified, only 8 studies were analyzed, including 519 patients comprising 250 with sarcopenia and 269 without sarcopenia. No obvious bias was observed in the included studies. An increased incidence of irAEs was not observed in patients with sarcopenia at pre-immunotherapy compared to those without sarcopenia. The OR and corresponding 95% CI were 0.97 and 0.62-1.53, respectively (P=0.90), with low heterogeneity (P=0.17, I2 =32%). Further, severe adverse events were analyzed in three studies, and the results showed that sarcopenia was not related to irAEs (P=0.97). CONCLUSIONS Malignancies with sarcopenia at pre-immunotherapy may not increase the incidence of irAEs, and sarcopenia may not be a predictive factor for irAEs.
Collapse
Affiliation(s)
- Shuluan Li
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
| | - Tianyu Wang
- Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
| | - Wenjuan Lai
- Nursing Department, Peking University Shenzhen Hospital, Shenzhen, China
| | - Mingying Zhang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
- Shantou University Medical College, Shantou, China
| | - Boran Cheng
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| |
Collapse
|
13
|
Li S, Wang T, Tong G, Li X, You D, Cong M. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021; 11:726257. [PMID: 34513704 PMCID: PMC8427761 DOI: 10.3389/fonc.2021.726257] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Accepted: 08/09/2021] [Indexed: 01/06/2023] Open
Abstract
Background The effect of sarcopenia on the clinical outcomes of patients with malignant neoplasms receiving immune checkpoint inhibitors (ICIs) is unclear. The aim of this study was to evaluate the effect and survival of patients with malignancies and sarcopenia receiving ICIs. Methods We systematically searched related studies in PubMed, Embase, and Cochrane Library up to March 2021 according to the inclusion and exclusion criteria. Information pertaining to the hazard ratio (HR) corresponding to 95% confidence interval (CI) of overall survival (OS) and progression-free survival (PFS) as determined by univariate and multivariate analyses; the odds ratio (OR) corresponding to the 95% CI of the disease control rate (DCR) and objective response rate (ORR); and immune-related adverse events (irAEs) was collected and analyzed using the RevMan 5.4 software. Study heterogeneity and sensitivity were also assessed. Results A total of 19 studies were finalized that included 1763patients with lung, gastrointestinal, and head and neck cancers as well as those with melanoma, renal cell carcinoma, urothelial carcinoma, pancreatic cancer, and soft tissue sarcoma. According to univariate and multivariate analyses, patients with sarcopenia at pre-immunotherapy had poorer PFS and OS than those without. HRs and the corresponding 95% CI of PFS were 1.91(1.55–2.34, p <0.00001) and 1.46 (1.20–1.78, p =0.0001), respectively, and HRs and the corresponding 95% CI of OS were 1.78 (1.47–2.14, p <0.00001) and 1.73 (1.36–2.19, p <0.0001), respectively. Patients with sarcopenia showed poor PFS and OS during treatment. In addition, patients with sarcopenia had worse ORR (OR 0.46, 95% CI 0.28–0.74, p = 0.001) and DCR (OR 0.44, 95% CI 0.31–0.64, p<0.0001); however, the incidence of irAEs of any grade and high-grade in patients with sarcopenia did not increase, OR and the corresponding 95% CI were 0.58(0.30–1.12, p = 0.10) and 0.46(0.19–1.09, p = 0.08). Further, we performed subgroup analysis, skeletal muscle mass index (SMI) and psoas muscle mass index (PMI) stratification. In the SMI group, patients with sarcopenia had poor ORR, DCR, PFS, and OS than those without. In the PMI group, sarcopenia had poor ORR,DCR, and was a poor prognostic factor for PFS and OS according to univariate analysis but had no effect on PFS and OS according to multivariate analysis. Conclusions Patients with malignancies and sarcopenia at pre-immunotherapy or follow-up visits had poorer clinical outcomes than those without, and sarcopenia was a poor predictive factor of ICI immunotherapy outcomes.
Collapse
Affiliation(s)
- Shuluan Li
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
| | - Tianyu Wang
- Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen, China
| | - Xiaoyu Li
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
| | - Danhui You
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
| | - Minghua Cong
- Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
14
|
Wang L, Dai C, Jiang L, Tong G, Xiong Y, Khan K, Tang Z, Chen X, Zeng H. Advanced Devices for Tumor Diagnosis and Therapy. Small 2021; 17:e2100003. [PMID: 34110694 DOI: 10.1002/smll.202100003] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/01/2021] [Revised: 02/04/2021] [Indexed: 06/12/2023]
Abstract
At present, tumor diagnosis is performed using common procedures, which are slow, costly, and still presenting difficulties in diagnosing tumors at their early stage. Tumor therapeutic methods also mainly rely on large-scale equipment or non-intelligent treatment approaches. Thus, an early and accurate tumor diagnosis and personalized treatment may represent the best treatment option for a successful result, and the efforts in finding them are still in progress and mainly focusing on non-destructive, integrated, and multiple technologies. These objectives can be achieved with the development of advanced devices and smart technology that represent the topic of the current investigations. Therefore, this review summarizes the progress in tumor diagnosis and therapy and briefly explains the advantages and disadvantages of the described microdevices, finally proposing advanced micro smart devices as the future development trend for tumor diagnosis and therapy.
Collapse
Affiliation(s)
- Lude Wang
- Institute of Optoelectronics & Nanomaterials, MIIT Key Laboratory of Advanced Display Materials and Devices, School of Materials Science and Engineering, Nanjing University of Science and Technology, Nanjing, 210094, China
- International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education, Institute of Microscale Optoelectronics, Shenzhen University, Shenzhen, 518060, China
| | - Chendong Dai
- Institute of Optoelectronics & Nanomaterials, MIIT Key Laboratory of Advanced Display Materials and Devices, School of Materials Science and Engineering, Nanjing University of Science and Technology, Nanjing, 210094, China
| | - Lianfu Jiang
- Institute of Optoelectronics & Nanomaterials, MIIT Key Laboratory of Advanced Display Materials and Devices, School of Materials Science and Engineering, Nanjing University of Science and Technology, Nanjing, 210094, China
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, 518036, China
| | - Yunhai Xiong
- Institute of Optoelectronics & Nanomaterials, MIIT Key Laboratory of Advanced Display Materials and Devices, School of Materials Science and Engineering, Nanjing University of Science and Technology, Nanjing, 210094, China
| | - Karim Khan
- International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education, Institute of Microscale Optoelectronics, Shenzhen University, Shenzhen, 518060, China
| | - Zhongmin Tang
- Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
| | - Xiang Chen
- Institute of Optoelectronics & Nanomaterials, MIIT Key Laboratory of Advanced Display Materials and Devices, School of Materials Science and Engineering, Nanjing University of Science and Technology, Nanjing, 210094, China
| | - Haibo Zeng
- Institute of Optoelectronics & Nanomaterials, MIIT Key Laboratory of Advanced Display Materials and Devices, School of Materials Science and Engineering, Nanjing University of Science and Technology, Nanjing, 210094, China
| |
Collapse
|
15
|
Lam A, Jayaraman P, Tong G, Ho V, Reuveny S, Oh S. Directed differentiation of pluripotent stem cells toward retinal pigment epithelium lineage by crispr activation. Cytotherapy 2021. [DOI: 10.1016/s1465324921004758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
16
|
Tong G, Luo Q, Pang X, Chen B, Lv G, Li X, Wang S. Retrospective Analyses of Complete Resection Combined with Systemic Chemotherapy and Targeted Therapy for Patients with Ovarian Metastases from Colorectal Cancer. Cancer Biother Radiopharm 2021; 37:553-559. [PMID: 33764806 DOI: 10.1089/cbr.2020.4013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Background: The aim of the study is to evaluate clinical outcomes of patients with ovarian metastases from colorectal cancer (OM-CRC) treated with complete resection combined with chemotherapy and targeted therapy. Methods: Fifty female patients with OM-CRC who were treated in two different hospitals were categorized into three groups: 14 patients with OM-CRC received resection and chemotherapy combined with targeted therapy, 16 patients with OM-CRC only received chemotherapy combined with targeted therapy, and 20 patients with non-OM-CRC (NOM-CRC) received chemotherapy combined with targeted therapy. The primary outcomes, including overall survival (OS), the objective response rate (ORR), disease control rate (DCR), safety, and progression-free survival (PFS), were observed. Results: The ORR of OM-CRC was significantly lower compared with NOM-CRC (36.7% vs. 70.0%, p = 0.021), and the DCR of OM-CRC was also lower compared with NOM-CRC (76.7% vs. 90.0%, p = 0.229). The following chemotherapy and targeted therapy in the additional surgical resection of OM-CRC were positively associated with longer PFS and OS compared to no surgical resection (9.0 vs. 6.0 months and 21.0 vs. 15.0 months, respectively, p < 0.001), but the PFS and OS were best in patients with NOM-CRC (9.0 and 35.0 months). Improved OS was associated with R0 resection (23.0 vs. 17.0 months, p < 0.001). Multivariate analysis indicated that patients with well-differentiated pathology and unilateral ovarian metastasis had a better prognosis. Conclusion: Multidisciplinary treatment strategy, including systemic chemotherapy, targeted therapy, and complete surgery, may contribute to the prolongation of OS and be safe for treatment of OM-CRC.
Collapse
Affiliation(s)
- Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Qianjiang Luo
- Department of Gastroenterology, the Peking University Shenzhen Hospital, Shenzhen, China
| | - Xionghao Pang
- Department of Oncology, Shenzhen Second People's Hospital, Shenzhen, China
| | - Boran Chen
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Guoqing Lv
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| | - Xi Li
- Department of Gastroenterology, the Peking University Shenzhen Hospital, Shenzhen, China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen, China
| |
Collapse
|
17
|
Lu Y, Liu F, Tong G, Qiu F, Song P, Wang X, Zou X, Wan D, Cui M, Xu Y, Zheng Z, Hong P. Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19. Signal Transduct Target Ther 2021; 6:107. [PMID: 33658482 PMCID: PMC7925812 DOI: 10.1038/s41392-021-00496-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/18/2020] [Accepted: 01/14/2021] [Indexed: 12/15/2022] Open
Abstract
Synthetic glucocorticoid dexamethasone is the first trial-proven drug that reduces COVID-19 mortality by suppressing immune system. In contrast, interferons are a crucial component of host antiviral immunity and can be directly suppressed by glucocorticoids. To investigate whether therapeutic interferons can compensate glucocorticoids-induced loss of antiviral immunity, we retrospectively analyzed a cohort of 387 PCR-confirmed COVID-19 patients with quasi-random exposure to interferons and conditional exposure to glucocorticoids. Among patients receiving glucocorticoids, early interferon therapy was associated with earlier hospital discharge (adjusted HR 1.68, 95% CI 1.19-2.37) and symptom relief (adjusted HR 1.48, 95% CI 1.06-2.08), while these associations were insignificant among glucocorticoids nonusers. Early interferon therapy was also associated with lower prevalence of prolonged viral shedding (adjusted OR 0.24, 95% CI 0.10-0.57) only among glucocorticoids users. Additionally, these associations were glucocorticoid cumulative dose- and timing-dependent. These findings reveal potential therapeutic synergy between interferons and glucocorticoids in COVID-19 that warrants further investigation.
Collapse
Affiliation(s)
- Yingying Lu
- Department of Biomedical Science, Shenzhen Research Institute, City University of Hong Kong, Kowloon Tong, Hong Kong, China
- Department of Nephrology, Center of Nephrology and Urology, Sun Yat-sen University Seventh Hospital, Shenzhen, Guangdong, China
| | - Feng Liu
- Department of Infectious Diseases, Suizhou Zengdu Hospital, Suizhou, Hubei, China
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
| | - Feng Qiu
- Department of Infectious Diseases, Suizhou Zengdu Hospital, Suizhou, Hubei, China
| | - Pinhong Song
- Department of Infectious Diseases, Suizhou Zengdu Hospital, Suizhou, Hubei, China
| | - Xiaolin Wang
- Intensive Care Unit, Suizhou Zengdu Hospital, Suizhou, Hubei, China
| | - Xiafei Zou
- Intensive Care Unit, Suizhou Zengdu Hospital, Suizhou, Hubei, China
| | - Deyun Wan
- Department of Respiratory Medicine, Suizhou Zengdu Hospital, Suizhou, Hubei, China
| | - Miao Cui
- Department of Pathology, Mount Sinai St. Luke's Roosevelt Hospital Center, New York, NY, USA
| | - Yunsheng Xu
- Department of Dermatology, Sun Yat-sen University Seventh Hospital, Shenzhen, Guangdong, China
| | - Zhihua Zheng
- Department of Nephrology, Center of Nephrology and Urology, Sun Yat-sen University Seventh Hospital, Shenzhen, Guangdong, China
| | - Peng Hong
- Department of Nephrology, Center of Nephrology and Urology, Sun Yat-sen University Seventh Hospital, Shenzhen, Guangdong, China.
- Division of Research and Development, US Department of Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY, USA.
- Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA.
| |
Collapse
|
18
|
Toprak M, Kashi M, Villanueva J, Wrzolek M, Tong G, Hamele-Bena D, Hoffman R, Hiltzik D. Thyroid and Parathyroid Neoplasms with Lipomatous Stroma: Report of Three Cases and Review of the Literature. Am J Clin Pathol 2020. [DOI: 10.1093/ajcp/aqaa161.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction/Objective
Tumors with mixed adipose tissue and epithelial components are rare in thyroid and parathyroid glands. Most of them are benign and referred to as adenolipoma (or lipoadenoma). A handful of malignant tumors of thyroid follicular cell origin have been reported with abundant adipose tissue known as thyroid carcinoma with lipomatous stroma (TCLS). Adenolipomas of thyroid or TCLS are usually manifested as large thyroid nodules and evaluated by fine needle aspiration biopsy (FNAB) which frequently yield low-cellularity samples due to abundant adipose tissue. On FNAB, the adipose tissue usually interpreted as contamination of subcutaneous or perithyroid origin. Similarly, adenolipomas of the parathyroid are not frequently identified because of presence of adipose tissue which is a feature associated with normal parathyroid glands. Therefore, these tumors are not often correctly diagnosed preoperatively. For that reason, pathologist should report additional cases about this rare entity to increase our understanding and to decrease preoperative diagnostic error.
Methods
We report three cases of thyroid and parathyroid tumors with abundant adipose tissue with sonographic, cytologic and histologic features along with literature review.
Results
Among the reported cases in the literature and our cases; 10 out of 17 cases of thyroid carcinoma with lipomatous stroma are papillary thyroid carcinomas (58.8%), 3 out of 17 cases are papillary microcarcinomas (17.6%), 2 out of 17 cases are noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (11.7%), and 2 out of 17 cases are minimally invasive follicular carcinomas (11.7%). No cases of poorly differentiated or anaplastic thyroid carcinomas have been reported.
Conclusion
Lipomatous stroma in thyroid carcinoma appears to be associated with differentiated carcinomas since no reported cases of poorly differentiated or anaplastic thyroid carcinomas are present to our knowledge. Although the presence of fatty tissue does not appear to alter the prognosis of these lesions, the question of the histogenesis of the adipose component is intriguing. Awareness of this unusual feature and increased utilization of multimodal approaches in the evaluation of this entity may increase preoperative detection and the understanding of the histogenesis and its possible significance.
Collapse
Affiliation(s)
- M Toprak
- Department of Pathology, Northwell Health - Staten Island University Hospital, Staten Island, New York, UNITED STATES
| | - M Kashi
- Department of Pathology, Northwell Health - Staten Island University Hospital, Staten Island, New York, UNITED STATES
| | - J Villanueva
- Department of Pathology, Northwell Health - Staten Island University Hospital, Staten Island, New York, UNITED STATES
| | - M Wrzolek
- Department of Pathology, Northwell Health - Staten Island University Hospital, Staten Island, New York, UNITED STATES
| | - G Tong
- Department of Pathology, Northwell Health - Staten Island University Hospital, Staten Island, New York, UNITED STATES
| | - D Hamele-Bena
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, UNITED STATES
| | - R Hoffman
- Center for Thyroid and Parathyroid disease, Northwell Health - Staten Island University Hospital, Staten Island, New York, UNITED STATES
| | - D Hiltzik
- Center for Thyroid and Parathyroid disease, Northwell Health - Staten Island University Hospital, Staten Island, New York, UNITED STATES
| |
Collapse
|
19
|
Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, Qiu F, Wang X, Zou X, Wan D, Qian X, Wang S, Guo Y, Yu H, Cui M, Tong G, Xu Y, Zheng Z, Lu Y, Hong P. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe 2020; 28:455-464.e2. [PMID: 32707096 PMCID: PMC7368656 DOI: 10.1016/j.chom.2020.07.005] [Citation(s) in RCA: 206] [Impact Index Per Article: 51.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 07/06/2020] [Accepted: 07/09/2020] [Indexed: 01/08/2023]
Abstract
Interferons (IFNs) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, a recent report of ACE2, the host factor mediating SARS-Cov-2 infection, identifying it as interferon-stimulated raised considerable safety concern. To examine the association between the use and timing of IFN-α2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study of 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (≤5 days after admission) of IFN-α2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-α2b, whereas late administration of IFN-α2b was associated with increased mortality. Among survivors, early IFN-α2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-α2b was associated with delayed recovery. Additionally, early IFN-α2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. We concluded that administration of IFN-α2b during the early stage of COVID-19 could induce favorable clinical responses.
Collapse
Affiliation(s)
- Nan Wang
- Department of Research, Sun Yat-sen University (SYSU) Seventh Hospital, Shenzhen, Guangdong 518107, China
| | - Yan Zhan
- Department of Rehabilitation Medicine, Xiangyang Central Hospital, Xiangyang, Hubei 441021, China; College of Medicine, Hubei University of Arts and Science, Xiangyang, Hubei 441053, China
| | - Linyu Zhu
- Department of Dermatology, SYSU Seventh Hospital, Shenzhen, Guangdong 518107, China
| | - Zhibing Hou
- Division of Quality Control, Xiangyang Central Blood Station, Xiangyang, Hubei 441000, China
| | - Feng Liu
- Department of Infectious Diseases, Fever Clinic, Suizhou Zengdu Hospital, Suizhou, Hubei 441300, China
| | - Pinhong Song
- Department of Infectious Diseases, Fever Clinic, Suizhou Zengdu Hospital, Suizhou, Hubei 441300, China
| | - Feng Qiu
- Department of Infectious Diseases, Fever Clinic, Suizhou Zengdu Hospital, Suizhou, Hubei 441300, China
| | - Xiaolin Wang
- Intensive Care Unit, Suizhou Zengdu Hospital, Suizhou, Hubei 441300, China
| | - Xiafei Zou
- Intensive Care Unit, Suizhou Zengdu Hospital, Suizhou, Hubei 441300, China
| | - Deyun Wan
- Department of Respiratory Medicine, Suizhou Zengdu Hospital, Suizhou, Hubei 441300, China
| | - Xiaosong Qian
- Department of Respiratory Medicine, Suizhou Zengdu Hospital, Suizhou, Hubei 441300, China
| | - Shanshan Wang
- Department of Rehabilitation Medicine, Xiangyang Central Hospital, Xiangyang, Hubei 441021, China
| | - Yabi Guo
- Department of Rehabilitation Medicine, Xiangyang Central Hospital, Xiangyang, Hubei 441021, China
| | - Hao Yu
- Department of Rehabilitation Medicine, Xiangyang Central Hospital, Xiangyang, Hubei 441021, China
| | - Miao Cui
- Department of Pathology, Mount Sinai St. Luke's Roosevelt Hospital Center, New York, NY 10025, USA
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China
| | - Yunsheng Xu
- Department of Research, Sun Yat-sen University (SYSU) Seventh Hospital, Shenzhen, Guangdong 518107, China; Department of Dermatology, SYSU Seventh Hospital, Shenzhen, Guangdong 518107, China
| | - Zhihua Zheng
- Department of Nephrology, Center of Nephrology and Urology, SYSU Seventh Hospital, Shenzhen, Guandgong, 518107, China
| | - Yingying Lu
- Department of Research, Sun Yat-sen University (SYSU) Seventh Hospital, Shenzhen, Guangdong 518107, China; Department of Biomedical Science, City University of Hong Kong, Kowloon, Hong Kong SAR, China
| | - Peng Hong
- Department of Research, Sun Yat-sen University (SYSU) Seventh Hospital, Shenzhen, Guangdong 518107, China; Division of Research and Development, US Department of Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY 11209, USA; Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, NY 11203, USA.
| |
Collapse
|
20
|
Wu X, Wu J, Tong G, Cheng B, Chen M, Yu S, He L, Li Z, Wang S. Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study. Cancer Manag Res 2020; 12:6575-6583. [PMID: 32801895 PMCID: PMC7402666 DOI: 10.2147/cmar.s254398] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 07/13/2020] [Indexed: 11/23/2022] Open
Abstract
Purpose Dexamethasone combined with 5-hydroxytryptamine type 3 receptor antagonists (5-HT3 RA) dual regimen is the standard prophylaxis regimen for patients receiving moderately emetogenic chemotherapy (MEC). However, it has been found in real-world practice that chemotherapy-induced nausea and vomiting (CINV) remains poorly controlled among patients with gastrointestinal tumor, especially in those with high-risk factors for vomiting, such as female, young, and non-alcoholic individuals. Hence, we aimed to evaluate the efficacy of an olanzapine-containing triple regimen in this clinical setting. Patients and Methods We retrospectively reviewed the clinical records of gastrointestinal tumor patients who received mFOLFOX6, XELOX, or FOLFIRI chemotherapy at two institutions. All patients included were female and less than 55 years old, with no history of drinking. The patients were divided into two groups for olanzapine-containing triple therapy (olanzapine, tropisetron, and dexamethasone) and non-olanzapine dual therapy (tropisetron and dexamethasone). The study outcomes were complete response (CR), complete control (CC), nausea control, and quality of life (QoL) by the functional living index-emesis (FLIE) questionnaire. Results A total of 93 patients were included in the study (olanzapine: 40; control: 53). The CR rate in the olanzapine group was significantly higher than that in the control group in delayed and overall phase (75.0% vs 54.7%, p=0.044; 70.0% vs 47.2%; p=0.028). The CC rate in the overall phase was also better in the olanzapine group (62.5% vs 39.6%, p=0.029). The control of nausea in the overall phase showed a superior trend in the olanzapine group (p=0.059). The olanzapine group exhibited higher FLIE scores, which demonstrated better QoL. More patients in the olanzapine group exhibited somnolence and dizziness. Conversely, the incidence of insomnia and anorexia in the olanzapine group was lower. Conclusion This retrospective study indicates that in gastrointestinal tumor patients with high-risk factors for CINV who were receiving MEC, olanzapine-containing triple antiemetic regimen exhibit better efficacy and QoL as compared to non-olanzapine dual regimen. Further randomized studies are required to confirm these results.
Collapse
Affiliation(s)
- Xuan Wu
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen 518036, People's Republic of China.,Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen 518036, People's Republic of China
| | - Jingxun Wu
- Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen 361003, People's Republic of China
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen 518036, People's Republic of China.,Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen 518036, People's Republic of China
| | - Boran Cheng
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen 518036, People's Republic of China.,Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen 518036, People's Republic of China
| | - Minhua Chen
- Community Healthcare Center, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, People's Republic of China
| | - Shaokang Yu
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen 518036, People's Republic of China.,Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen 518036, People's Republic of China
| | - Lirui He
- Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China
| | - Zhu Li
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen 518036, People's Republic of China.,Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen 518036, People's Republic of China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China.,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Shenzhen 518036, People's Republic of China.,Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen 518036, People's Republic of China
| |
Collapse
|
21
|
Tong G, Li S, Lin L, He L, Wang L, Lv G, Zheng R, Wang S. Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study. Cancer Manag Res 2020; 12:2481-2489. [PMID: 32308484 PMCID: PMC7152553 DOI: 10.2147/cmar.s239420] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 03/02/2020] [Indexed: 12/19/2022] Open
Abstract
Background The aim of this study was to evaluate the efficacy and safety of trastuzumab, combined with the FLOT regimen, in the perioperative treatment of resectable HER-2-positive advanced gastric cancer. Methods Overall, 45 patients were divided into two groups; 29 patients in the experimental group were treated with trastuzumab combined with FLOT and 16 patients in the control group were treated with FLOT alone. The primary endpoint was objective response rate (ORR), and the secondary endpoints were disease control rate (DCR), tumor regression grade (TRG), surgical margin, side effects, and overall survival. Results In the experimental and control groups, ORR was 72.4% and 43.8% (p=0.226), DCR was 89.7% and 87.5%, R0 resection rate was 96.5% and 93.7%, total/subtotal tumor regression grade was 17.2% and 6.3%, partial tumor regression grade was 27.6% and 18.7% (p=0.468), and 2-year survival rate was 78.1% and 73.9% (p=0.932), respectively. The common side effects were agranulocytosis and vomiting. There was no significant difference between the two groups. Conclusion Trastuzumab combined with FLOT has a good curative effect and safety profile in the perioperative treatment of patients with resectable HER-2-positive advanced gastric cancer. In addition, trastuzumab + FLOT had the same result as FLOT alone, as there was no significant benefit with the addition of T in the group studied.
Collapse
Affiliation(s)
- Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, People's Republic of China
| | - Shuluan Li
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, People's Republic of China
| | - Lin Lin
- Department of Oncology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518036, People's Republic of China
| | - Lirui He
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, People's Republic of China
| | - Li Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, People's Republic of China
| | - Guoqing Lv
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, People's Republic of China
| | - Ruinian Zheng
- Department of Oncology, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, Guangdong 523000, People's Republic of China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, People's Republic of China
| |
Collapse
|
22
|
Song Y, Hu C, Xie Z, Wu L, Zhu Z, Rao C, Liu L, Chen Y, Liang N, Chen J, Hu C, Yang N, Hu J, Zhao W, Tong G, Dong X, Zheng D, Jin M, Chen J, Huang M, He Y, Rosell R, Lippi G, Mino-Kenudson M, Han-Zhang H, Mao X, Zhang L, Liu H, Field JK, Chuai S, Ye J, Han Y, Lu S. Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Transl Lung Cancer Res 2020; 9:269-279. [PMID: 32420066 PMCID: PMC7225135 DOI: 10.21037/tlcr.2020.03.17] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Background Although growth advantage of certain clones would ultimately translate into a clinically visible disease progression, radiological imaging does not reflect clonal evolution at molecular level. Circulating tumor DNA (ctDNA), validated as a tool for mutation detection in lung cancer, could reflect dynamic molecular changes. We evaluated the utility of ctDNA as a predictive and a prognostic marker in disease monitoring of advanced non-small cell lung cancer (NSCLC) patients. Methods This is a multicenter prospective cohort study. We performed capture-based ultra-deep sequencing on longitudinal plasma samples utilizing a panel consisting of 168 NSCLC-related genes on 949 advanced NSCLC patients with driver mutations to monitor treatment responses and disease progression. The correlations between ctDNA and progression-free survival (PFS)/overall survival (OS) were performed on 248 patients undergoing various treatments with the minimum of 2 ctDNA tests. Results The results of this study revealed that higher ctDNA abundance (P=0.012) and mutation count (P=8.5×10−4) at baseline are associated with shorter OS. We also found that patients with ctDNA clearance, not just driver mutation clearance, at any point during the course of treatment were associated with longer PFS (P=2.2×10−16, HR 0.28) and OS (P=4.5×10−6, HR 0.19) regardless of type of treatment and evaluation schedule. Conclusions This prospective real-world study shows that ctDNA clearance during treatment may serve as predictive and prognostic marker across a wide spectrum of treatment regimens.
Collapse
Affiliation(s)
- Yong Song
- Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of the Medicine, Nanjing 210002, China
| | - Chengping Hu
- Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China
| | - Zhanhong Xie
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Lin Wu
- Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China
| | - Zhengfei Zhu
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
| | - Chuangzhou Rao
- Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo 315010, China
| | - Li Liu
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Yuan Chen
- Department of Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Naixin Liang
- Department of Thoracic Surgery, Peking Union Medical College Hospital Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
| | - Jun Chen
- Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Chunhong Hu
- Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha 410008, China
| | - Nong Yang
- Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China
| | - Jie Hu
- Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - Weixin Zhao
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, China
| | - Xiaorong Dong
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Di Zheng
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
| | - Meiling Jin
- Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - Jianhua Chen
- Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China
| | - Meijuan Huang
- Department of Oncology, West China Hospital, Chengdu 610041, China
| | - Yong He
- Department of Respiratory Medicine, Daping Hospital, Army Medical University, Chongqing 400042, China
| | - Rafael Rosell
- Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias I Pujol Health Sciences Institute and Hospital Badalona, Barcelona, Spain
| | - Giuseppe Lippi
- Section of Clinical Biochemistry, University of Verona, Verona, Italy
| | | | | | - Xinru Mao
- Burning Rock Biotech, Guangzhou 510300, China
| | - Lu Zhang
- Burning Rock Biotech, Guangzhou 510300, China
| | - Hao Liu
- Burning Rock Biotech, Guangzhou 510300, China
| | - John K Field
- Roy Castle Lung Cancer Research Program, The University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Liverpool, UK
| | | | - Junyi Ye
- Burning Rock Biotech, Guangzhou 510300, China
| | - Yusheng Han
- Burning Rock Biotech, Guangzhou 510300, China
| | - Shun Lu
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
| | | |
Collapse
|
23
|
Krech J, Lam P, Tong G, Berger F, Rosenthal LM, Schmitt K. Cardiomyocytes: The Heart of DAMPs Release and Sterile Inflammation in Ischemia/Reperfusion Injury. Thorac Cardiovasc Surg 2020. [DOI: 10.1055/s-0040-1705527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
24
|
Tong G, Cheng B, Li J, Wu X, Nong Q, He L, Li X, Li L, Wang S. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells. Cancer Med 2019; 8:7044-7054. [PMID: 31557409 PMCID: PMC6853821 DOI: 10.1002/cam4.2542] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2019] [Revised: 07/19/2019] [Accepted: 08/08/2019] [Indexed: 12/18/2022] Open
Abstract
Background Immunotherapy and its mechanisms are being studied in a wide variety of cancers. Programmed cell death ligand 1 (PDL1) is associated with immune evasion in numerous tumor types. Here, we aimed to assess the relationship between metastasis associated in colon cancer‐1 (MACC1) and PDL1 and examine their effects on gastric cancer (GC) tumor immunity. Methods The expression of MACC1, c‐Met, and PDL1 in human GC tissues was first assessed using quantitative RT‐PCR (qRT‐PCR) and immunohistochemistry. We then focused on the relationships among MACC1, c‐Met, and PDL1 using RT‐PCR and western blotting after cell transfection and inhibitor treatment in vitro and on the identification of their roles in immune killing in vitro and in vivo. Results We found that expression of MACC1, c‐Met, and PDL1 was upregulated in human GC tissues, and there was a positive correlation between the expression levels. In addition, we found that ectopic expression of MACC1 (silencing and overexpression by transfection) resulted in corresponding changes in c‐Met and PDL1 expression levels, and c‐Met/AKT/mTOR pathway inhibitors (SU11274, MK2206, and rapamycin) blocked the regulation of PDL1 expression by MACC1. Furthermore, silencing of MACC1 led to an increase in antitumor and immune killing in vitro and in vivo, and overexpression of MACC1 resulted in a decrease in tumor immunity in vitro and in vivo. Conclusions From these data, we infer that MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in GC cells and suggest that MACC1 may be a therapeutic target for GC immunotherapy.
Collapse
Affiliation(s)
- Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Boran Cheng
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Jingzhang Li
- Department of Oncology, Liuzhou People's Hospital, Liuzhou, China
| | - Xuan Wu
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Qiaohong Nong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Lirui He
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Xi Li
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Laiqing Li
- Guangzhou Youdi Bio-technology Co., Ltd, Guangzhou, China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China
| |
Collapse
|
25
|
Cheng B, Tong G, Wu X, Cai W, Li Z, Tong Z, He L, Yu S, Wang S. Enumeration And Characterization Of Circulating Tumor Cells And Its Application In Advanced Gastric Cancer. Onco Targets Ther 2019; 12:7887-7896. [PMID: 31576146 PMCID: PMC6768312 DOI: 10.2147/ott.s223222] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 09/13/2019] [Indexed: 01/27/2023] Open
Abstract
Background Advanced gastric cancer (aGC) has a high global incidence and a high mortality rate and because of its high malignancy and heterogeneity, the existing methods for prognosis are limited, and a new treatment model is necessary. Circulating tumor cells (CTCs) could be considered as a “liquid biopsy” for tumor diagnosis and for monitoring treatment responses and predicting clinical outcome. Clinical studies support the efficacy of programmed cell death 1 (PD-1) immunotherapy in a subset of aGC. Methods Cell capture efficiency, as described by the CanPatrol CTC enrichment technique, was validated using artificial blood samples as well as blood samples from 32 aGC patients. Clinicopathologic data of patients were collected from the hospital information system. We used CanPatrol for CTC isolation, classification, and clinical analysis. Results A cell capture efficiency of >80% was achieved. Significant correlation was observed between CTC enumeration and clinicopathology parameters, including the Lauren classification (r=0.470, P=0.008), perineural invasion (r=0.393, P=0.029), TNM stage (r=0.740, P<0.001), and Ki-67 level (r=0.510, P=0.005). When compared to the traditional methods, monitoring CTC subtypes exhibits higher sensitivity of evaluating the disease status. Enumeration of epithelial CTC subset and its relative abundance in the total CTC pool are highly correlated with clinical efficacy. CTC programmed cell death ligand-1 (PD-L1) could be successfully detected for immunotherapy in addition to PD-L1 immunohistochemistry and microsatellite instability. Conclusion We provide a new method that allows for the simple and effective detection of CTCs in aGC. It has potential clinical applications in monitoring prognosis and guiding future individualized immunotherapy.
Collapse
Affiliation(s)
- Boran Cheng
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China
| | - Gangling Tong
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China
| | - Xuan Wu
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China
| | - Wenwu Cai
- Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province 410011, People's Republic of China
| | - Zhu Li
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China
| | - Zhongyi Tong
- Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province 410011, People's Republic of China
| | - Lirui He
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China
| | - Shaokang Yu
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China
| | - Shubin Wang
- Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China
| |
Collapse
|
26
|
Li J, Tong G, Huang C, Luo Y, Wang S, Zhang Y, Cheng B, Zhang Z, Wu X, Liu Q, Li M, Li L, Ni B. HOXC10 promotes cell migration, invasion, and tumor growth in gastric carcinoma cells through upregulating proinflammatory cytokines. J Cell Physiol 2019; 235:3579-3591. [PMID: 31552684 DOI: 10.1002/jcp.29246] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Accepted: 09/03/2019] [Indexed: 12/25/2022]
Affiliation(s)
- Jingzhang Li
- Department of Oncology, Liuzhou People's Hospital The Affiliated Liuzhou People's Hospital of Guangxi Medical University Liuzhou Guangxi China
| | - Gangling Tong
- Department of Oncology, Shenzhen Hospital Peking University Shenzhen Guangdong China
| | - Cheng Huang
- Department of Oncology, Liuzhou People's Hospital The Affiliated Liuzhou People's Hospital of Guangxi Medical University Liuzhou Guangxi China
| | - Yunsheng Luo
- Department of Gastrointestinal Surgery, Liuzhou People's Hospital The Affiliated Liuzhou People’ Hospital of Guangxi Medical University Liuzhou Guangxi China
| | - Shubin Wang
- Department of Oncology, Shenzhen Hospital Peking University Shenzhen Guangdong China
| | - Ying Zhang
- Department of Pathology, Liuzhou People's Hospital The Affiliated Liuzhou People’ Hospital of Guangxi Medical University Liuzhou Guangxi China
| | - Boran Cheng
- Department of Oncology, Shenzhen Hospital Peking University Shenzhen Guangdong China
| | - Zhihong Zhang
- Department of Oncology, Liuzhou People's Hospital The Affiliated Liuzhou People's Hospital of Guangxi Medical University Liuzhou Guangxi China
| | - Xuan Wu
- Department of Oncology, Shenzhen Hospital Peking University Shenzhen Guangdong China
| | - Qiumei Liu
- Department of Oncology, Liuzhou People's Hospital The Affiliated Liuzhou People's Hospital of Guangxi Medical University Liuzhou Guangxi China
| | - Min Li
- Department of Oncology, Liuzhou People's Hospital The Affiliated Liuzhou People's Hospital of Guangxi Medical University Liuzhou Guangxi China
| | - Laiqing Li
- Department of Scientific Research Guangzhou Youdi Bio‐Technology Co., Ltd. Guangzhou Guangdong China
| | - Bingqiang Ni
- Department of Oncology, Liuzhou People's Hospital The Affiliated Liuzhou People's Hospital of Guangxi Medical University Liuzhou Guangxi China
| |
Collapse
|
27
|
Byrne M, Jackson H, Sinha A, Tong G, Grafton-Clarke C, Rees S, Mathur A, Cross B, Christopher E, Isaacs L, Banh S, Sheng Z, Lundin R. The National Student Association of Medical Research (NSAMR) Publication Pathway. Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Tong G, Wu X, Cheng B, Li L, Li X, Li Z, Nong Q, Chen X, Liu Y, Wang S. Knockdown of HOXA-AS2 suppresses proliferation and induces apoptosis in colorectal cancer. Am J Transl Res 2017; 9:4545-4552. [PMID: 29118916 PMCID: PMC5666063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Accepted: 06/22/2017] [Indexed: 06/07/2023]
Abstract
Colorectal cancer (CRC) remains one of the most common cancers worldwide. Increasing evidence indicates that long non-coding RNAs (lncRNAs) regulate diverse cellular processes, including cell growth, differentiation, apoptosis, and cancer progression. However, the function of lncRNAs in the progression of CRC remains largely unknown. Here, we reported that HOXA cluster antisense RNA2 (HOXA-AS2) was upregulated in CRC. Increased HOXA-AS2 expression in CRC was associated with larger tumor size and higher clinical stage. In vitro experiments revealed that HOXA-AS2 knockdown significantly inhibited CRC cell proliferation by causing G1 arrest and promoting apoptosis, whereas HOXA-AS2 overexpression promoted cell proliferation. Further functional assays indicated that HOXA-AS2 overexpression significantly promoted cell migration and invasion by regulating the epithelial-mesenchymal transition (EMT). In conclusion, our study identifies HOXA-AS2C as a potential biomarker in CRC.
Collapse
Affiliation(s)
- Gangling Tong
- Department of Medical Oncology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| | - Xuan Wu
- Department of Medical Oncology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| | - Boran Cheng
- Department of Medical Oncology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| | - Liang Li
- Department of Digestive Oncology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| | - Xi Li
- Department of Gastroenterology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| | - Zhu Li
- Department of Medical Oncology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| | - Qiaohong Nong
- Department of Medical Oncology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| | - Xiaoqiu Chen
- Department of Medical Oncology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| | - Yajie Liu
- Department of Medical Oncology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| | - Shubin Wang
- Department of Medical Oncology, Peking University Shenzhen HospitalShenzhen, Guangdong, China
| |
Collapse
|
29
|
Lin L, Tong G, Li M, Liu A, Wang S. MiR-495-3p facilitates colon cancer cell proliferation via Wnt/β-catenin signaling pathway by restraining Wnt inhibitory factor. TROP J PHARM RES 2017. [DOI: 10.4314/tjpr.v16i9.10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
30
|
Tong G, Krauss A, Mochner J, Wollersheim S, Soltani P, Berger F, Schmitt KRL. Deep hypothermia therapy attenuates LPS-induced microglia neuroinflammation via the STAT3 pathway. Neuroscience 2017; 358:201-210. [PMID: 28687308 DOI: 10.1016/j.neuroscience.2017.06.055] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Revised: 06/08/2017] [Accepted: 06/28/2017] [Indexed: 11/25/2022]
Abstract
Deep hypothermia therapy (HT) is a standard method for neuroprotection during complex pediatric cardiac surgery involving extracorporeal circulation and deep hypothermic cardiac arrest. The procedure, however, can provoke systemic inflammatory response syndrome (SIRS), one of the most severe side effects associated with pediatric cardiac surgery. To date, the cellular inflammatory mechanisms induced by deep HT remain to be elucidated. Therefore, we investigated the effects of deep HT (17°C) and rewarming on the inflammatory response in lipopolysaccharide (LPS) stimulated BV-2 murine microglia. Additionally, we also investigated the application of Stattic, a signal transducer and activator of transcription 3 (STAT3) activation inhibitor, as an alternative to physical cooling to attenuate the LPS-induced inflammatory response. Deep HT had no cytotoxic effect but attenuated microglia migration. IκBα degradation was delayed by deep HT resulting in the attenuation of pNF-κB p65 migration into the nucleus and significant decreases in pro-inflammatory IL-6, TNF-α, and MCP-1 expressions and secretions, as well as decreased anti-inflammatory IL-10 and SOCS3 expressions. Additionally, pStat3 was significantly down regulated under deep hypothermic conditions, also corresponding with the significant reduction in IL-6 and TNF-α expressions. Similar to the effects of HT, the application of Stattic under normothermic conditions resulted in significantly reduced IL-6 and TNF-α expressions. Moreover, attenuation of the inflammatory response resulted in decreased apoptosis in a direct co-culture of microglia and neurons. HT reduces the inflammatory response in LPS-stimulated BV-2 microglial cells, alluding to a possible mechanism of therapeutic hypothermia-induced neuroprotection. In the future, attenuating the phospho-STAT3 pathway may lead to the development of a neuroprotectant with greater clinical efficacy.
Collapse
Affiliation(s)
- G Tong
- Department of Congenital Heart Disease/Pediatric Cardiology, German Heart Institute Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
| | - A Krauss
- Department of Congenital Heart Disease/Pediatric Cardiology, German Heart Institute Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
| | - J Mochner
- Department of Congenital Heart Disease/Pediatric Cardiology, German Heart Institute Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
| | - S Wollersheim
- Department of Congenital Heart Disease/Pediatric Cardiology, German Heart Institute Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
| | - P Soltani
- Department of Pediatric Cardiology, Charité Medical University Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
| | - F Berger
- Department of Congenital Heart Disease/Pediatric Cardiology, German Heart Institute Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; Department of Pediatric Cardiology, Charité Medical University Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
| | - K R L Schmitt
- Department of Congenital Heart Disease/Pediatric Cardiology, German Heart Institute Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
| |
Collapse
|
31
|
Lu S, Song Y, Xie Z, Li M, Zhu Z, LIU LI, Dong X, Chen Y, Zheng D, Zhao W, Chang JH, Jin M, Hu J, Tong G, Rao C, Xu H, Zhang L, Mao X, Han-Zhang H, Liu H. Association of circulating tumor DNA clearance during treatment with improved progression-free survival in advanced non-small cell lung cancer patients. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.11528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11528 Background: Currently, response assessment of patients with non-small cell lung cancer (NSCLC) primarily relies on imaging scans, which do not reflect biological processes at the molecular level. We utilized circulating tumor DNA (ctDNA) coupled with capture-based ultra deep next generation sequencing to conduct dynamic monitoring of treatment response, thus evaluating the ability of ctDNA as a tumor clonal response biomarker. Methods: We performed capture-based sequencing on longitudinal plasma samples, including baseline and a minimum of 2 evaluation points, obtained from 88 patients with advanced NSCLC using a ctDNA panel, spanning 160KB of human genome and consisting of critical exons and introns from 168 genes. This real world study comprises a highly heterogeneous cohort with a mixture of prior treatment exposure. Results: At baseline, treatment-naïve patients often harbor solo driver mutation; in contrast, patients with prior treatments are more likely to harbor concurrent driver mutations. Patients who received molecular targeted therapy according to the baseline sequencing results have a longer progression-free survival (PFS) (p = 0.0001), demonstrating the value of ctDNA in directing treatment. During subsequent evaluations, we observed 74% concordance rate between molecular and radiographic responses. Furthermore, our data revealed that during follow-up, patients with at least one time of undetectable ctDNA are associated with a longer PFS (p = 5.52e-6), regardless the type of treatment commenced. Among 44 patients who had at least one time of undetectable ctDNA, 39 achieved partial response or stable disease as their best response. Collectively, this phenomenon reflects clonal response, thus demonstrating the biological nature underlying the clinical response assessed by imaging modalities. Conclusions: This real world study demonstrates that patients with at least one time of ctDNA clearance during subsequent evaluation are associated with a longer PFS. Our study warrants further investigations to explore the value of ctDNA clearance as a surrogate endpoint of efficacy and as a risk stratification factor.
Collapse
Affiliation(s)
- Shun Lu
- Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Yong Song
- Nanjing Military General Hospital, Nanjing, China
| | - Zhanhong Xie
- Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Min Li
- Xiangya Hospital, Cental South University, Changsha, China
| | - Zhengfei Zhu
- Fudan University Shanghai Cancer Center, Shanghai, China
| | - LI LIU
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xiaorong Dong
- Union Hospital Tongji Medical College Huazhong Universtiy of Science and Technology, Wuahn, China
| | - Yuan Chen
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Di Zheng
- Shanghai Pulmonary Hospital, Shanghai, China
| | - Weixin Zhao
- Fudan University Shanghai Cancer Center, Shanghai, China
| | - Jian Hua Chang
- Fudan University Shanghai Cancer Center, Shanghai, China
| | | | - Jie Hu
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Gangling Tong
- Department of Medical Oncology, Peking Univeristy Shenzhen Hospital, Shenzhen, China
| | - Chuangzhou Rao
- Department of Radiotherapy, Ningbo No.2 Hospital, Ningbo, China
| | - Haiyan Xu
- Burning Rock Biotech, Guangzhou, China
| | - Lu Zhang
- Burning Rock Biotech, Guangzhou, China
| | - Xinru Mao
- Burning Rock Biotech, Guangzhou, China
| | | | - Hao Liu
- Burning Rock Biotech, Guangzhou, China
| |
Collapse
|
32
|
Rosenthal LM, Walker C, Tong G, Berger F, Schmitt K. Moderate Hypothermia after Hypoxia Is Neuroprotective Possibly via Upregulation of Cold Shock Protein RBM3. Thorac Cardiovasc Surg 2017. [DOI: 10.1055/s-0037-1598979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- L.-M. Rosenthal
- Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany
| | - C. Walker
- Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany
| | - G. Tong
- Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany
| | - F. Berger
- Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany
| | - K.R.L. Schmitt
- Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany
| |
Collapse
|
33
|
Krech J, Cormann SB, Walker C, Tong G, Berger F, Schmitt K. Cardioprotective Effect of Intraischemic Therapeutic Hypothermia in Primary Cardiomyocytes. Thorac Cardiovasc Surg 2016. [DOI: 10.1055/s-0036-1571881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
34
|
Schmitt K, Tong G, Feldmann M, Walker C, Berger F. Intra-ischemia vs post-ischemia hypothermia induced neurological and cardiac protection via the up-regulation of RBM3. Thorac Cardiovasc Surg 2014. [DOI: 10.1055/s-0034-1394019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
35
|
Schubert S, Wowro S, Tong G, Berger F, Schmitt K. Combination of mTOR Inhibitor and Calcineurin Inhibitor in EBV-positive and EBV-negative B-lymphocytes. J Heart Lung Transplant 2014. [DOI: 10.1016/j.healun.2014.01.663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
36
|
Walker C, Tong G, Wollersheim S, Berger F, Schmitt K. Moderate Hypothermia Diminishes Death of Cardiomyocytes following Ischemia. Thorac Cardiovasc Surg 2013. [DOI: 10.1055/s-0033-1354495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
37
|
Krauss A, Mochner J, Wollersheim S, Tong G, Berger F, Schmitt K. Stattic: Can a New Drug Reduce the Inflammatory Responses after Cardiopulmonary Bypass Surgery? Thorac Cardiovasc Surg 2013. [DOI: 10.1055/s-0033-1354506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Fabig V, Drescher C, Krauss A, Tong G, Walker C, Berger F, Schmitt K. Cardioprotective Effect of Early Moderate Hypothermia during Ischemia. Thorac Cardiovasc Surg 2013. [DOI: 10.1055/s-0033-1354494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Rungatscher A, Tong G, Linardi D, Milani E, Shmitt K, Hallstroem S, Faggian G. Pharmacologically induced hypothermia with cannabinoid receptor agonist WIN55,212-2 improves outcome compared to mild therapeutic hypothermia after cardiac arrest. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p4028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Tong G, Savant I, Jariwala N, Burt D, Zheng N, Buzescu A, Bertz R, Keswani S, Marcus R. Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects. J Headache Pain 2013. [PMCID: PMC3619991 DOI: 10.1186/1129-2377-14-s1-p118] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
41
|
Tong G, Savant I, Jariwala N, Burt D, Zheng N, Buzescu A, Bertz R, Keswani S, Marcus R. Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects. J Headache Pain 2013. [DOI: 10.1186/1129-2377-1-s1-p118] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
42
|
Galic V, Shawber C, Shah M, Wright J, Herzog T, Kitajewski J, Tong G. NOTCH2 as a tumor suppressor in epithelial ovarian cancer. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Bi Y, Zeng L, Zhu D, Yan J, Zhang Y, Tong G, Mu P, Shen S, Hu Y, Yu Q, Liang H, Weng J. Association of β-cell function and insulin sensitivity with fasting and 2-h plasma glucose in a large Chinese population. Diabetes Obes Metab 2012; 14:174-80. [PMID: 21951345 DOI: 10.1111/j.1463-1326.2011.01504.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
AIM Our aim was to provide a quantitative analysis of the changes in the principal determinants of insulin sensitivity and secretion in relation to fasting plasma glucose (FPG) or 2-h plasma glucose (2h PG) in a Chinese population with a wide range of glucose tolerance. METHODS A total of 5728 adults spanning the entire range of glucose tolerance were included. Insulin sensitivity was measured by Matsuda insulin sensitivity index (ISI(M)) and homeostasis model assessment of 1/homeostasis model assessment of insulin resistance (HOMA-IR). β-Cell function adjusted by insulin sensitivity was assessed from disposition index (DI) at early-phase DI(30) and total DI(120). The exponential curve was established as the best fit for the relationship between insulin sensitivity or β-cell function and FPG or 2h PG. RESULTS Relative to the trend classified as increasing 2h PG, hepatic insulin sensitivity and insulin secretion showed a decreasing trend to a substantial degree as FPG increased. A 1 mmol/l increase in FPG and 2h PG concentration was associated with a -22 and -21% decline in ISI(M), -16 and -4% in 1/HOMA-IR, -38 and -35% in DI(30) and -36 and -26% in DI(120). The decay constant of ISI(M) and DI(30) in IFG or ISI(M), 1/HOMA-IR, DI(30) and DI(120) in IGT was lower than that in normal glucose tolerance. Significant interactions between sex and glucose levels determining DI were found. CONCLUSIONS We conclude that impairment of insulin sensitivity and insulin secretion contributes to both FPG or 2h PG hyperglycaemia in a Chinese population, but that the decline in insulin secretion is more pronounced with increasing fasting than 2h PG.
Collapse
Affiliation(s)
- Y Bi
- Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M, Abramowicz H, Abreu H, Acerbi E, Acharya BS, Adams DL, Addy TN, Adelman J, Aderholz M, Adomeit S, Adragna P, Adye T, Aefsky S, Aguilar-Saavedra JA, Aharrouche M, Ahlen SP, Ahles F, Ahmad A, Ahsan M, Aielli G, Akdogan T, Akesson TPA, Akimoto G, Akimov AV, Akiyama A, Alam MS, Alam MA, Albert J, Albrand S, Aleksa M, Aleksandrov IN, Alessandria F, Alexa C, Alexander G, Alexandre G, Alexopoulos T, Alhroob M, Aliev M, Alimonti G, Alison J, Aliyev M, Allport PP, Allwood-Spiers SE, Almond J, Aloisio A, Alon R, Alonso A, Alvarez Gonzalez B, Alviggi MG, Amako K, Amaral P, Amelung C, Ammosov VV, Amorim A, Amorós G, Amram N, Anastopoulos C, Ancu LS, Andari N, Andeen T, Anders CF, Anders G, Anderson KJ, Andreazza A, Andrei V, Andrieux ML, Anduaga XS, Angerami A, Anghinolfi F, Anjos N, Annovi A, Antonaki A, Antonelli M, Antonov A, Antos J, Anulli F, Aoun S, Aperio Bella L, Apolle R, Arabidze G, Aracena I, Arai Y, Arce ATH, Archambault JP, Arfaoui S, Arguin JF, Arik E, Arik M, Armbruster AJ, Arnaez O, Artamonov A, Artoni G, Arutinov D, Asai S, Asfandiyarov R, Ask S, Asman B, Asquith L, Assamagan K, Astbury A, Astvatsatourov A, Atoian G, Aubert B, Auge E, Augsten K, Aurousseau M, Avolio G, Avramidou R, Axen D, Ay C, Azuelos G, Azuma Y, Baak MA, Baccaglioni G, Bacci C, Bach AM, Bachacou H, Bachas K, Bachy G, Backes M, Backhaus M, Badescu E, Bagnaia P, Bahinipati S, Bai Y, Bailey DC, Bain T, Baines JT, Baker OK, Baker MD, Baker S, Banas E, Banerjee P, Banerjee S, Banfi D, Bangert A, Bansal V, Bansil HS, Barak L, Baranov SP, Barashkou A, Barbaro Galtieri A, Barber T, Barberio EL, Barberis D, Barbero M, Bardin DY, Barillari T, Barisonzi M, Barklow T, Barlow N, Barnett BM, Barnett RM, Baroncelli A, Barone G, Barr AJ, Barreiro F, Barreiro Guimarães da Costa J, Bartoldus R, Barton AE, Bartsch V, Bates RL, Batkova L, Batley JR, Battaglia A, Battistin M, Battistoni G, Bauer F, Bawa HS, Beare B, Beau T, Beauchemin PH, Beccherle R, Bechtle P, Beck HP, Becker S, Beckingham M, Becks KH, Beddall AJ, Beddall A, Bedikian S, Bednyakov VA, Bee CP, Begel M, Behar Harpaz S, Behera PK, Beimforde M, Belanger-Champagne C, Bell PJ, Bell WH, Bella G, Bellagamba L, Bellina F, Bellomo M, Belloni A, Beloborodova O, Belotskiy K, Beltramello O, Ben Ami S, Benary O, Benchekroun D, Benchouk C, Bendel M, Benekos N, Benhammou Y, Benjamin DP, Benoit M, Bensinger JR, Benslama K, Bentvelsen S, Berge D, Bergeaas Kuutmann E, Berger N, Berghaus F, Berglund E, Beringer J, Bernat P, Bernhard R, Bernius C, Berry T, Bertin A, Bertinelli F, Bertolucci F, Besana MI, Besson N, Bethke S, Bhimji W, Bianchi RM, Bianco M, Biebel O, Bieniek SP, Bierwagen K, Biesiada J, Biglietti M, Bilokon H, Bindi M, Binet S, Bingul A, Bini C, Biscarat C, Bitenc U, Black KM, Blair RE, Blanchard JB, Blanchot G, Blazek T, Blocker C, Blocki J, Blondel A, Blum W, Blumenschein U, Bobbink GJ, Bobrovnikov VB, Bocchetta SS, Bocci A, Boddy CR, Boehler M, Boek J, Boelaert N, Böser S, Bogaerts JA, Bogdanchikov A, Bogouch A, Bohm C, Boisvert V, Bold T, Boldea V, Bolnet NM, Bona M, Bondarenko VG, Bondioli M, Boonekamp M, Boorman G, Booth CN, Bordoni S, Borer C, Borisov A, Borissov G, Borjanovic I, Borroni S, Bos K, Boscherini D, Bosman M, Boterenbrood H, Botterill D, Bouchami J, Boudreau J, Bouhova-Thacker EV, Bourdarios C, Bousson N, Boveia A, Boyd J, Boyko IR, Bozhko NI, Bozovic-Jelisavcic I, Bracinik J, Braem A, Branchini P, Brandenburg GW, Brandt A, Brandt G, Brandt O, Bratzler U, Brau B, Brau JE, Braun HM, Brelier B, Bremer J, Brenner R, Bressler S, Breton D, Britton D, Brochu FM, Brock I, Brock R, Brodbeck TJ, Brodet E, Broggi F, Bromberg C, Brooijmans G, Brooks WK, Brown G, Brown H, Bruckman de Renstrom PA, Bruncko D, Bruneliere R, Brunet S, Bruni A, Bruni G, Bruschi M, Buanes T, Bucci F, Buchanan J, Buchanan NJ, Buchholz P, Buckingham RM, Buckley AG, Buda SI, Budagov IA, Budick B, Büscher V, Bugge L, Buira-Clark D, Bulekov O, Bunse M, Buran T, Burckhart H, Burdin S, Burgess T, Burke S, Busato E, Bussey P, Buszello CP, Butin F, Butler B, Butler JM, Buttar CM, Butterworth JM, Buttinger W, Cabrera Urbán S, Caforio D, Cakir O, Calafiura P, Calderini G, Calfayan P, Calkins R, Caloba LP, Caloi R, Calvet D, Calvet S, Camacho Toro R, Camarri P, Cambiaghi M, Cameron D, Caminada LM, Campana S, Campanelli M, Canale V, Canelli F, Canepa A, Cantero J, Capasso L, Capeans Garrido MDM, Caprini I, Caprini M, Capriotti D, Capua M, Caputo R, Cardarelli R, Carli T, Carlino G, Carminati L, Caron B, Caron S, Carrillo Montoya GD, Carter AA, Carter JR, Carvalho J, Casadei D, Casado MP, Cascella M, Caso C, Castaneda Hernandez AM, Castaneda-Miranda E, Castillo Gimenez V, Castro NF, Cataldi G, Cataneo F, Catinaccio A, Catmore JR, Cattai A, Cattani G, Caughron S, Cauz D, Cavalleri P, Cavalli D, Cavalli-Sforza M, Cavasinni V, Ceradini F, Cerqueira AS, Cerri A, Cerrito L, Cerutti F, Cetin SA, Cevenini F, Chafaq A, Chakraborty D, Chan K, Chapleau B, Chapman JD, Chapman JW, Chareyre E, Charlton DG, Chavda V, Chavez Barajas CA, Cheatham S, Chekanov S, Chekulaev SV, Chelkov GA, Chelstowska MA, Chen C, Chen H, Chen S, Chen T, Chen X, Cheng S, Cheplakov A, Chepurnov VF, Cherkaoui El Moursli R, Chernyatin V, Cheu E, Cheung SL, Chevalier L, Chiefari G, Chikovani L, Childers JT, Chilingarov A, Chiodini G, Chizhov MV, Choudalakis G, Chouridou S, Christidi IA, Christov A, Chromek-Burckhart D, Chu ML, Chudoba J, Ciapetti G, Ciba K, Ciftci AK, Ciftci R, Cinca D, Cindro V, Ciobotaru MD, Ciocca C, Ciocio A, Cirilli M, Ciubancan M, Clark A, Clark PJ, Cleland W, Clemens JC, Clement B, Clement C, Clifft RW, Coadou Y, Cobal M, Coccaro A, Cochran J, Coe P, Cogan JG, Coggeshall J, Cogneras E, Cojocaru CD, Colas J, Colijn AP, Collard C, Collins NJ, Collins-Tooth C, Collot J, Colon G, Conde Muiño P, Coniavitis E, Conidi MC, Consonni M, Consorti V, Constantinescu S, Conta C, Conventi F, Cook J, Cooke M, Cooper BD, Cooper-Sarkar AM, Copic K, Cornelissen T, Corradi M, Corriveau F, Cortes-Gonzalez A, Cortiana G, Costa G, Costa MJ, Costanzo D, Costin T, Côté D, Courneyea L, Cowan G, Cowden C, Cox BE, Cranmer K, Crescioli F, Cristinziani M, Crosetti G, Crupi R, Crépé-Renaudin S, Cuciuc CM, Cuenca Almenar C, Cuhadar Donszelmann T, Curatolo M, Curtis CJ, Cwetanski P, Czirr H, Czyczula Z, D'Auria S, D'Onofrio M, D'Orazio A, Da Silva PVM, Da Via C, Dabrowski W, Dai T, Dallapiccola C, Dam M, Dameri M, Damiani DS, Danielsson HO, Dannheim D, Dao V, Darbo G, Darlea GL, Daum C, Davidek T, Davidson N, Davidson R, Davies E, Davies M, Davison AR, Davygora Y, Dawe E, Dawson I, Dawson JW, Daya RK, De K, de Asmundis R, De Castro S, De Castro Faria Salgado PE, De Cecco S, de Graat J, De Groot N, de Jong P, De La Taille C, De la Torre H, De Lotto B, De Mora L, De Nooij L, De Pedis D, De Salvo A, De Sanctis U, De Santo A, De Vivie De Regie JB, Dean S, Debbe R, Debenedetti C, Dedovich DV, Degenhardt J, Dehchar M, Del Papa C, Del Peso J, Del Prete T, Delemontex T, Deliyergiyev M, Dell'acqua A, Dell'Asta L, Della Pietra M, della Volpe D, Delmastro M, Delruelle N, Delsart PA, Deluca C, Demers S, Demichev M, Demirkoz B, Deng J, Denisov SP, Derendarz D, Derkaoui JE, Derue F, Dervan P, Desch K, Devetak E, Deviveiros PO, Dewhurst A, Dewilde B, Dhaliwal S, Dhullipudi R, Di Ciaccio A, Di Ciaccio L, Di Girolamo A, Di Girolamo B, Di Luise S, Di Mattia A, Di Micco B, Di Nardo R, Di Simone A, Di Sipio R, Diaz MA, Diblen F, Diehl EB, Dietrich J, Dietzsch TA, Dindar Yagci K, Dingfelder J, Dionisi C, Dita P, Dita S, Dittus F, Djama F, Djobava T, do Vale MAB, Do Valle Wemans A, Doan TKO, Dobbs M, Dobinson R, Dobos D, Dobson E, Dobson M, Dodd J, Doglioni C, Doherty T, Doi Y, Dolejsi J, Dolenc I, Dolezal Z, Dolgoshein BA, Dohmae T, Donadelli M, Donega M, Donini J, Dopke J, Doria A, Dos Anjos A, Dosil M, Dotti A, Dova MT, Dowell JD, Doxiadis AD, Doyle AT, Drasal Z, Drees J, Dressnandt N, Drevermann H, Driouichi C, Dris M, Dubbert J, Dube S, Duchovni E, Duckeck G, Dudarev A, Dudziak F, Dührssen M, Duerdoth IP, Duflot L, Dufour MA, Dunford M, Duran Yildiz H, Duxfield R, Dwuznik M, Dydak F, Düren M, Ebenstein WL, Ebke J, Eckweiler S, Edmonds K, Edwards CA, Edwards NC, Ehrenfeld W, Ehrich T, Eifert T, Eigen G, Einsweiler K, Eisenhandler E, Ekelof T, El Kacimi M, Ellert M, Elles S, Ellinghaus F, Ellis K, Ellis N, Elmsheuser J, Elsing M, Emeliyanov D, Engelmann R, Engl A, Epp B, Eppig A, Erdmann J, Ereditato A, Eriksson D, Ernst J, Ernst M, Ernwein J, Errede D, Errede S, Ertel E, Escalier M, Escobar C, Espinal Curull X, Esposito B, Etienne F, Etienvre AI, Etzion E, Evangelakou D, Evans H, Fabbri L, Fabre C, Fakhrutdinov RM, Falciano S, Fang Y, Fanti M, Farbin A, Farilla A, Farley J, Farooque T, Farrington SM, Farthouat P, Fassnacht P, Fassouliotis D, Fatholahzadeh B, Favareto A, Fayard L, Fazio S, Febbraro R, Federic P, Fedin OL, Fedorko W, Fehling-Kaschek M, Feligioni L, Feng C, Feng EJ, Fenyuk AB, Ferencei J, Ferland J, Fernando W, Ferrag S, Ferrando J, Ferrara V, Ferrari A, Ferrari P, Ferrari R, Ferrer A, Ferrer ML, Ferrere D, Ferretti C, Ferretto Parodi A, Fiascaris M, Fiedler F, Filipčič A, Filippas A, Filthaut F, Fincke-Keeler M, Fiolhais MCN, Fiorini L, Firan A, Fischer G, Fischer P, Fisher MJ, Flechl M, Fleck I, Fleckner J, Fleischmann P, Fleischmann S, Flick T, Flores Castillo LR, Flowerdew MJ, Fokitis M, Fonseca Martin T, Forbush DA, Formica A, Forti A, Fortin D, Foster JM, Fournier D, Foussat A, Fowler AJ, Fowler K, Fox H, Francavilla P, Franchino S, Francis D, Frank T, Franklin M, Franz S, Fraternali M, Fratina S, French ST, Friedrich F, Froeschl R, Froidevaux D, Frost JA, Fukunaga C, Fullana Torregrosa E, Fuster J, Gabaldon C, Gabizon O, Gadfort T, Gadomski S, Gagliardi G, Gagnon P, Galea C, Gallas EJ, Gallo V, Gallop BJ, Gallus P, Gan KK, Gao YS, Gapienko VA, Gaponenko A, Garberson F, Garcia-Sciveres M, García C, García Navarro JE, Gardner RW, Garelli N, Garitaonandia H, Garonne V, Garvey J, Gatti C, Gaudio G, Gaumer O, Gaur B, Gauthier L, Gavrilenko IL, Gay C, Gaycken G, Gayde JC, Gazis EN, Ge P, Gee CNP, Geerts DAA, Geich-Gimbel C, Gellerstedt K, Gemme C, Gemmell A, Genest MH, Gentile S, George M, George S, Gerlach P, Gershon A, Geweniger C, Ghazlane H, Ghez P, Ghodbane N, Giacobbe B, Giagu S, Giakoumopoulou V, Giangiobbe V, Gianotti F, Gibbard B, Gibson A, Gibson SM, Gilbert LM, Gilewsky V, Gillberg D, Gillman AR, Gingrich DM, Ginzburg J, Giokaris N, Giordani MP, Giordano R, Giorgi FM, Giovannini P, Giraud PF, Giugni D, Giunta M, Giusti P, Gjelsten BK, Gladilin LK, Glasman C, Glatzer J, Glazov A, Glitza KW, Glonti GL, Godfrey J, Godlewski J, Goebel M, Göpfert T, Goeringer C, Gössling C, Göttfert T, Goldfarb S, Golling T, Golovnia SN, Gomes A, Gomez Fajardo LS, Gonçalo R, Goncalves Pinto Firmino Da Costa J, Gonella L, Gonidec A, Gonzalez S, González de la Hoz S, Gonzalez Parra G, Gonzalez Silva ML, Gonzalez-Sevilla S, Goodson JJ, Goossens L, Gorbounov PA, Gordon HA, Gorelov I, Gorfine G, Gorini B, Gorini E, Gorišek A, Gornicki E, Gorokhov SA, Goryachev VN, Gosdzik B, Gosselink M, Gostkin MI, Gough Eschrich I, Gouighri M, Goujdami D, Goulette MP, Goussiou AG, Goy C, Gozpinar S, Grabowska-Bold I, Grafström P, Grahn KJ, Grancagnolo F, Grancagnolo S, Grassi V, Gratchev V, Grau N, Gray HM, Gray JA, Graziani E, Grebenyuk OG, Greenshaw T, Greenwood ZD, Gregersen K, Gregor IM, Grenier P, Griffiths J, Grigalashvili N, Grillo AA, Grinstein S, Grishkevich YV, Grivaz JF, Groh M, Gross E, Grosse-Knetter J, Groth-Jensen J, Grybel K, Guarino VJ, Guest D, Guicheney C, Guida A, Guillemin T, Guindon S, Guler H, Gunther J, Guo B, Guo J, Gupta A, Gusakov Y, Gushchin VN, Gutierrez A, Gutierrez P, Guttman N, Gutzwiller O, Guyot C, Gwenlan C, Gwilliam CB, Haas A, Haas S, Haber C, Hackenburg R, Hadavand HK, Hadley DR, Haefner P, Hahn F, Haider S, Hajduk Z, Hakobyan H, Haller J, Hamacher K, Hamal P, Hamer M, Hamilton A, Hamilton S, Han H, Han L, Hanagaki K, Hanawa K, Hance M, Handel C, Hanke P, Hansen JR, Hansen JB, Hansen JD, Hansen PH, Hansson P, Hara K, Hare GA, Harenberg T, Harkusha S, Harper D, Harrington RD, Harris OM, Harrison K, Hartert J, Hartjes F, Haruyama T, Harvey A, Hasegawa S, Hasegawa Y, Hassani S, Hatch M, Hauff D, Haug S, Hauschild M, Hauser R, Havranek M, Hawes BM, Hawkes CM, Hawkings RJ, Hawkins D, Hayakawa T, Hayashi T, Hayden D, Hayward HS, Haywood SJ, Hazen E, He M, Head SJ, Hedberg V, Heelan L, Heim S, Heinemann B, Heisterkamp S, Helary L, Hellman S, Hellmich D, Helsens C, Henderson RCW, Henke M, Henrichs A, Henriques Correia AM, Henrot-Versille S, Henry-Couannier F, Hensel C, Henß T, Hernandez CM, Hernández Jiménez Y, Herrberg R, Hershenhorn AD, Herten G, Hertenberger R, Hervas L, Hessey NP, Higón-Rodriguez E, Hill D, Hill JC, Hill N, Hiller KH, Hillert S, Hillier SJ, Hinchliffe I, Hines E, Hirose M, Hirsch F, Hirschbuehl D, Hobbs J, Hod N, Hodgkinson MC, Hodgson P, Hoecker A, Hoeferkamp MR, Hoffman J, Hoffmann D, Hohlfeld M, Holder M, Holmgren SO, Holy T, Holzbauer JL, Homma Y, Hong TM, Hooft van Huysduynen L, Horazdovsky T, Horn C, Horner S, Horton K, Hostachy JY, Hou S, Houlden MA, Hoummada A, Howarth J, Howell DF, Hristova I, Hrivnac J, Hruska I, Hryn'ova T, Hsu PJ, Hsu SC, Huang GS, Hubacek Z, Hubaut F, Huegging F, Huffman TB, Hughes EW, Hughes G, Hughes-Jones RE, Huhtinen M, Hurst P, Hurwitz M, Husemann U, Huseynov N, Huston J, Huth J, Iacobucci G, Iakovidis G, Ibbotson M, Ibragimov I, Ichimiya R, Iconomidou-Fayard L, Idarraga J, Iengo P, Igonkina O, Ikegami Y, Ikeno M, Ilchenko Y, Iliadis D, Imbault D, Imori M, Ince T, Inigo-Golfin J, Ioannou P, Iodice M, Irles Quiles A, Isaksson C, Ishikawa A, Ishino M, Ishmukhametov R, Issever C, Istin S, Ivashin AV, Iwanski W, Iwasaki H, Izen JM, Izzo V, Jackson B, Jackson JN, Jackson P, Jaekel MR, Jain V, Jakobs K, Jakobsen S, Jakubek J, Jana DK, Jankowski E, Jansen E, Jantsch A, Janus M, Jarlskog G, Jeanty L, Jelen K, Jen-La Plante I, Jenni P, Jeremie A, Jež P, Jézéquel S, Jha MK, Ji H, Ji W, Jia J, Jiang Y, Jimenez Belenguer M, Jin G, Jin S, Jinnouchi O, Joergensen MD, Joffe D, Johansen LG, Johansen M, Johansson KE, Johansson P, Johnert S, Johns KA, Jon-And K, Jones G, Jones RWL, Jones TW, Jones TJ, Jonsson O, Joram C, Jorge PM, Joseph J, Jovin T, Ju X, Jung CA, Juranek V, Jussel P, Juste Rozas A, Kabachenko VV, Kabana S, Kaci M, Kaczmarska A, Kadlecik P, Kado M, Kagan H, Kagan M, Kaiser S, Kajomovitz E, Kalinin S, Kalinovskaya LV, Kama S, Kanaya N, Kaneda M, Kanno T, Kantserov VA, Kanzaki J, Kaplan B, Kapliy A, Kaplon J, Kar D, Karagoz M, Karnevskiy M, Karr K, Kartvelishvili V, Karyukhin AN, Kashif L, Kasieczka G, Kasmi A, Kass RD, Kastanas A, Kataoka M, Kataoka Y, Katsoufis E, Katzy J, Kaushik V, Kawagoe K, Kawamoto T, Kawamura G, Kayl MS, Kazanin VA, Kazarinov MY, Keates JR, Keeler R, Kehoe R, Keil M, Kekelidze GD, Kennedy J, Kenney CJ, Kenyon M, Kepka O, Kerschen N, Kerševan BP, Kersten S, Kessoku K, Keung J, Khakzad M, Khalil-Zada F, Khandanyan H, Khanov A, Kharchenko D, Khodinov A, Kholodenko AG, Khomich A, Khoo TJ, Khoriauli G, Khoroshilov A, Khovanskiy N, Khovanskiy V, Khramov E, Khubua J, Kim H, Kim MS, Kim PC, Kim SH, Kimura N, Kind O, King BT, King M, King RSB, Kirk J, Kirsch LE, Kiryunin AE, Kishimoto T, Kisielewska D, Kittelmann T, Kiver AM, Kladiva E, Klaiber-Lodewigs J, Klein M, Klein U, Kleinknecht K, Klemetti M, Klier A, Klimentov A, Klingenberg R, Klinkby EB, Klioutchnikova T, Klok PF, Klous S, Kluge EE, Kluge T, Kluit P, Kluth S, Knecht NS, Kneringer E, Knobloch J, Knoops EBFG, Knue A, Ko BR, Kobayashi T, Kobel M, Kocian M, Kodys P, Köneke K, König AC, Koenig S, Köpke L, Koetsveld F, Koevesarki P, Koffas T, Koffeman E, Kohn F, Kohout Z, Kohriki T, Koi T, Kokott T, Kolachev GM, Kolanoski H, Kolesnikov V, Koletsou I, Koll J, Kollar D, Kollefrath M, Kolya SD, Komar AA, Komori Y, Kondo T, Kono T, Kononov AI, Konoplich R, Konstantinidis N, Kootz A, Koperny S, Kopikov SV, Korcyl K, Kordas K, Koreshev V, Korn A, Korol A, Korolkov I, Korolkova EV, Korotkov VA, Kortner O, Kortner S, Kostyukhin VV, Kotamäki MJ, Kotov S, Kotov VM, Kotwal A, Kourkoumelis C, Kouskoura V, Koutsman A, Kowalewski R, Kowalski TZ, Kozanecki W, Kozhin AS, Kral V, Kramarenko VA, Kramberger G, Krasny MW, Krasznahorkay A, Kraus J, Kraus JK, Kreisel A, Krejci F, Kretzschmar J, Krieger N, Krieger P, Kroeninger K, Kroha H, Kroll J, Kroseberg J, Krstic J, Kruchonak U, Krüger H, Kruker T, Krumshteyn ZV, Kruth A, Kubota T, Kuehn S, Kugel A, Kuhl T, Kuhn D, Kukhtin V, Kulchitsky Y, Kuleshov S, Kummer C, Kuna M, Kundu N, Kunkle J, Kupco A, Kurashige H, Kurata M, Kurochkin YA, Kus V, Kuze M, Kvita J, Kwee R, La Rosa A, La Rotonda L, Labarga L, Labbe J, Lablak S, Lacasta C, Lacava F, Lacker H, Lacour D, Lacuesta VR, Ladygin E, Lafaye R, Laforge B, Lagouri T, Lai S, Laisne E, Lamanna M, Lampen CL, Lampl W, Lancon E, Landgraf U, Landon MPJ, Landsman H, Lane JL, Lange C, Lankford AJ, Lanni F, Lantzsch K, Laplace S, Lapoire C, Laporte JF, Lari T, Larionov AV, Larner A, Lasseur C, Lassnig M, Laurelli P, Lavrijsen W, Laycock P, Lazarev AB, Le Dortz O, Le Guirriec E, Le Maner C, Le Menedeu E, Lebel C, Lecompte T, Ledroit-Guillon F, Lee H, Lee JSH, Lee SC, Lee L, Lefebvre M, Legendre M, Leger A, Legeyt BC, Legger F, Leggett C, Lehmacher M, Lehmann Miotto G, Lei X, Leite MAL, Leitner R, Lellouch D, Leltchouk M, Lemmer B, Lendermann V, Leney KJC, Lenz T, Lenzen G, Lenzi B, Leonhardt K, Leontsinis S, Leroy C, Lessard JR, Lesser J, Lester CG, Leung Fook Cheong A, Levêque J, Levin D, Levinson LJ, Levitski MS, Lewis A, Lewis GH, Leyko AM, Leyton M, Li B, Li H, Li S, Li X, Liang Z, Liang Z, Liao H, Liberti B, Lichard P, Lichtnecker M, Lie K, Liebig W, Lifshitz R, Lilley JN, Limbach C, Limosani A, Limper M, Lin SC, Linde F, Linnemann JT, Lipeles E, Lipinsky L, Lipniacka A, Liss TM, Lissauer D, Lister A, Litke AM, Liu C, Liu D, Liu H, Liu JB, Liu M, Liu S, Liu Y, Livan M, Livermore SSA, Lleres A, Llorente Merino J, Lloyd SL, Lobodzinska E, Loch P, Lockman WS, Loddenkoetter T, Loebinger FK, Loginov A, Loh CW, Lohse T, Lohwasser K, Lokajicek M, Loken J, Lombardo VP, Long RE, Lopes L, Lopez Mateos D, Losada M, Loscutoff P, Lo Sterzo F, Losty MJ, Lou X, Lounis A, Loureiro KF, Love J, Love PA, Lowe AJ, Lu F, Lubatti HJ, Luci C, Lucotte A, Ludwig A, Ludwig D, Ludwig I, Ludwig J, Luehring F, Luijckx G, Lumb D, Luminari L, Lund E, Lund-Jensen B, Lundberg B, Lundberg J, Lundquist J, Lungwitz M, Lutz G, Lynn D, Lys J, Lytken E, Ma H, Ma LL, Macana Goia JA, Maccarrone G, Macchiolo A, Maček B, Machado Miguens J, Mackeprang R, Madaras RJ, Mader WF, Maenner R, Maeno T, Mättig P, Mättig S, Magnoni L, Magradze E, Mahalalel Y, Mahboubi K, Mahout G, Maiani C, Maidantchik C, Maio A, Majewski S, Makida Y, Makovec N, Mal P, Malecki P, Malecki P, Maleev VP, Malek F, Mallik U, Malon D, Malone C, Maltezos S, Malyshev V, Malyukov S, Mameghani R, Mamuzic J, Manabe A, Mandelli L, Mandić I, Mandrysch R, Maneira J, Mangeard PS, Manjavidze ID, Mann A, Manning PM, Manousakis-Katsikakis A, Mansoulie B, Manz A, Mapelli A, Mapelli L, March L, Marchand JF, Marchese F, Marchiori G, Marcisovsky M, Marin A, Marino CP, Marroquim F, Marshall R, Marshall Z, Martens FK, Marti-Garcia S, Martin AJ, Martin B, Martin B, Martin FF, Martin JP, Martin P, Martin TA, Martin VJ, Martin Dit Latour B, Martin-Haugh S, Martinez M, Martinez Outschoorn V, Martyniuk AC, Marx M, Marzano F, Marzin A, Masetti L, Mashimo T, Mashinistov R, Masik J, Maslennikov AL, Massa I, Massaro G, Massol N, Mastrandrea P, Mastroberardino A, Masubuchi T, Mathes M, Matsumoto H, Matsunaga H, Matsushita T, Mattravers C, Maugain JM, Maurer J, Maxfield SJ, Maximov DA, May EN, Mayne A, Mazini R, Mazur M, Mazzanti M, Mazzoni E, Mc Kee SP, McCarn A, McCarthy RL, McCarthy TG, McCubbin NA, McFarlane KW, McFayden JA, McGlone H, McHedlidze G, McLaren RA, McLaughlan T, McMahon SJ, McPherson RA, Meade A, Mechnich J, Mechtel M, Medinnis M, Meera-Lebbai R, Meguro T, Mehdiyev R, Mehlhase S, Mehta A, Meier K, Meirose B, Melachrinos C, Mellado Garcia BR, Mendoza Navas L, Meng Z, Mengarelli A, Menke S, Menot C, Meoni E, Mercurio KM, Mermod P, Merola L, Meroni C, Merritt FS, Messina A, Metcalfe J, Mete AS, Meyer C, Meyer C, Meyer JP, Meyer J, Meyer J, Meyer TC, Meyer WT, Miao J, Michal S, Micu L, Middleton RP, Miele P, Migas S, Mijović L, Mikenberg G, Mikestikova M, Mikuž M, Miller DW, Miller RJ, Mills WJ, Mills C, Milov A, Milstead DA, Milstein D, Minaenko AA, Miñano M, Minashvili IA, Mincer AI, Mindur B, Mineev M, Ming Y, Mir LM, Mirabelli G, Miralles Verge L, Misiejuk A, Mitrevski J, Mitrofanov GY, Mitsou VA, Mitsui S, Miyagawa PS, Miyazaki K, Mjörnmark JU, Moa T, Mockett P, Moed S, Moeller V, Mönig K, Möser N, Mohapatra S, Mohr W, Mohrdieck-Möck S, Moisseev AM, Moles-Valls R, Molina-Perez J, Monk J, Monnier E, Montesano S, Monticelli F, Monzani S, Moore RW, Moorhead GF, Mora Herrera C, Moraes A, Morange N, Morel J, Morello G, Moreno D, Moreno Llácer M, Morettini P, Morii M, Morin J, Morley AK, Mornacchi G, Morozov SV, Morris JD, Morvaj L, Moser HG, Mosidze M, Moss J, Mount R, Mountricha E, Mouraviev SV, Moyse EJW, Mudrinic M, Mueller F, Mueller J, Mueller K, Müller TA, Muenstermann D, Muir A, Munwes Y, Murray WJ, Mussche I, Musto E, Myagkov AG, Myska M, Nadal J, Nagai K, Nagano K, Nagasaka Y, Nairz AM, Nakahama Y, Nakamura K, Nakamura T, Nakano I, Nanava G, Napier A, Nash M, Nation NR, Nattermann T, Naumann T, Navarro G, Neal HA, Nebot E, Nechaeva PY, Negri A, Negri G, Nektarijevic S, Nelson A, Nelson S, Nelson TK, Nemecek S, Nemethy P, Nepomuceno AA, Nessi M, Neubauer MS, Neusiedl A, Neves RM, Nevski P, Newman PR, Nguyen Thi Hong V, Nickerson RB, Nicolaidou R, Nicolas L, Nicquevert B, Niedercorn F, Nielsen J, Niinikoski T, Nikiforou N, Nikiforov A, Nikolaenko V, Nikolaev K, Nikolic-Audit I, Nikolics K, Nikolopoulos K, Nilsen H, Nilsson P, Ninomiya Y, Nisati A, Nishiyama T, Nisius R, Nodulman L, Nomachi M, Nomidis I, Nordberg M, Nordkvist B, Norton PR, Novakova J, Nozaki M, Nozka L, Nugent IM, Nuncio-Quiroz AE, Nunes Hanninger G, Nunnemann T, Nurse E, Nyman T, O'Brien BJ, O'Neale SW, O'Neil DC, O'Shea V, Oakham FG, Oberlack H, Ocariz J, Ochi A, Oda S, Odaka S, Odier J, Ogren H, Oh A, Oh SH, Ohm CC, Ohshima T, Ohshita H, Ohsugi T, Okada S, Okawa H, Okumura Y, Okuyama T, Olariu A, Olcese M, Olchevski AG, Oliveira M, Oliveira Damazio D, Oliver Garcia E, Olivito D, Olszewski A, Olszowska J, Omachi C, Onofre A, Onyisi PUE, Oram CJ, Oreglia MJ, Oren Y, Orestano D, Orlov I, Oropeza Barrera C, Orr RS, Osculati B, Ospanov R, Osuna C, Otero Y Garzon G, Ottersbach JP, Ouchrif M, Ould-Saada F, Ouraou A, Ouyang Q, Owen M, Owen S, Ozcan VE, Ozturk N, Pacheco Pages A, Padilla Aranda C, Pagan Griso S, Paganis E, Paige F, Pais P, Pajchel K, Palacino G, Paleari CP, Palestini S, Pallin D, Palma A, Palmer JD, Pan YB, Panagiotopoulou E, Panes B, Panikashvili N, Panitkin S, Pantea D, Panuskova M, Paolone V, Papadelis A, Papadopoulou TD, Paramonov A, Park W, Parker MA, Parodi F, Parsons JA, Parzefall U, Pasqualucci E, Passeri A, Pastore F, Pastore F, Pásztor G, Pataraia S, Patel N, Pater JR, Patricelli S, Pauly T, Pecsy M, Pedraza Morales MI, Peleganchuk SV, Peng H, Pengo R, Penson A, Penwell J, Perantoni M, Perez K, Perez Cavalcanti T, Perez Codina E, Pérez García-Estañ MT, Perez Reale V, Perini L, Pernegger H, Perrino R, Perrodo P, Persembe S, Peshekhonov VD, Petersen BA, Petersen J, Petersen TC, Petit E, Petridis A, Petridou C, Petrolo E, Petrucci F, Petschull D, Petteni M, Pezoa R, Phan A, Phillips AW, Phillips PW, Piacquadio G, Piccaro E, Piccinini M, Piec SM, Piegaia R, Pilcher JE, Pilkington AD, Pina J, Pinamonti M, Pinder A, Pinfold JL, Ping J, Pinto B, Pirotte O, Pizio C, Placakyte R, Plamondon M, Pleier MA, Pleskach AV, Poblaguev A, Poddar S, Podlyski F, Poggioli L, Poghosyan T, Pohl M, Polci F, Polesello G, Policicchio A, Polini A, Poll J, Polychronakos V, Pomarede DM, Pomeroy D, Pommès K, Pontecorvo L, Pope BG, Popeneciu GA, Popovic DS, Poppleton A, Portell Bueso X, Posch C, Pospelov GE, Pospisil S, Potrap IN, Potter CJ, Potter CT, Poulard G, Poveda J, Prabhu R, Pralavorio P, Prasad S, Pravahan R, Prell S, Pretzl K, Pribyl L, Price D, Price LE, Price MJ, Prieur D, Primavera M, Prokofiev K, Prokoshin F, Protopopescu S, Proudfoot J, Prudent X, Przysiezniak H, Psoroulas S, Ptacek E, Pueschel E, Purdham J, Purohit M, Puzo P, Pylypchenko Y, Qian J, Qian Z, Qin Z, Quadt A, Quarrie DR, Quayle WB, Quinonez F, Raas M, Radescu V, Radics B, Rador T, Ragusa F, Rahal G, Rahimi AM, Rahm D, Rajagopalan S, Rammensee M, Rammes M, Ramstedt M, Randle-Conde AS, Randrianarivony K, Ratoff PN, Rauscher F, Raymond M, Read AL, Rebuzzi DM, Redelbach A, Redlinger G, Reece R, Reeves K, Reichold A, Reinherz-Aronis E, Reinsch A, Reisinger I, Reljic D, Rembser C, Ren ZL, Renaud A, Renkel P, Rescigno M, Resconi S, Resende B, Reznicek P, Rezvani R, Richards A, Richter R, Richter-Was E, Ridel M, Rijpstra M, Rijssenbeek M, Rimoldi A, Rinaldi L, Rios RR, Riu I, Rivoltella G, Rizatdinova F, Rizvi E, Robertson SH, Robichaud-Veronneau A, Robinson D, Robinson JEM, Robinson M, Robson A, Rocha de Lima JG, Roda C, Roda Dos Santos D, Rodier S, Rodriguez D, Roe A, Roe S, Røhne O, Rojo V, Rolli S, Romaniouk A, Romano M, Romanov VM, Romeo G, Roos L, Ros E, Rosati S, Rosbach K, Rose A, Rose M, Rosenbaum GA, Rosenberg EI, Rosendahl PL, Rosenthal O, Rosselet L, Rossetti V, Rossi E, Rossi LP, Rotaru M, Roth I, Rothberg J, Rousseau D, Royon CR, Rozanov A, Rozen Y, Ruan X, Rubinskiy I, Ruckert B, Ruckstuhl N, Rud VI, Rudolph C, Rudolph G, Rühr F, Ruggieri F, Ruiz-Martinez A, Rumiantsev V, Rumyantsev L, Runge K, Runolfsson O, Rurikova Z, Rusakovich NA, Rust DR, Rutherfoord JP, Ruwiedel C, Ruzicka P, Ryabov YF, Ryadovikov V, Ryan P, Rybar M, Rybkin G, Ryder NC, Rzaeva S, Saavedra AF, Sadeh I, Sadrozinski HFW, Sadykov R, Safai Tehrani F, Sakamoto H, Salamanna G, Salamon A, Saleem M, Salihagic D, Salnikov A, Salt J, Salvachua Ferrando BM, Salvatore D, Salvatore F, Salvucci A, Salzburger A, Sampsonidis D, Samset BH, Sanchez A, Sandaker H, Sander HG, Sanders MP, Sandhoff M, Sandoval T, Sandoval C, Sandstroem R, Sandvoss S, Sankey DPC, Sansoni A, Santamarina Rios C, Santoni C, Santonico R, Santos H, Saraiva JG, Sarangi T, Sarkisyan-Grinbaum E, Sarri F, Sartisohn G, Sasaki O, Sasaki T, Sasao N, Satsounkevitch I, Sauvage G, Sauvan E, Sauvan JB, Savard P, Savinov V, Savu DO, Sawyer L, Saxon DH, Says LP, Sbarra C, Sbrizzi A, Scallon O, Scannicchio DA, Schaarschmidt J, Schacht P, Schäfer U, Schaepe S, Schaetzel S, Schaffer AC, Schaile D, Schamberger RD, Schamov AG, Scharf V, Schegelsky VA, Scheirich D, Schernau M, Scherzer MI, Schiavi C, Schieck J, Schioppa M, Schlenker S, Schlereth JL, Schmidt E, Schmieden K, Schmitt C, Schmitt S, Schmitz M, Schöning A, Schott M, Schouten D, Schovancova J, Schram M, Schroeder C, Schroer N, Schuh S, Schuler G, Schultes J, Schultz-Coulon HC, Schulz H, Schumacher JW, Schumacher M, Schumm BA, Schune P, Schwanenberger C, Schwartzman A, Schwemling P, Schwienhorst R, Schwierz R, Schwindling J, Schwindt T, Scott WG, Searcy J, Sedov G, Sedykh E, Segura E, Seidel SC, Seiden A, Seifert F, Seixas JM, Sekhniaidze G, Seliverstov DM, Sellden B, Sellers G, Seman M, Semprini-Cesari N, Serfon C, Serin L, Seuster R, Severini H, Sevior ME, Sfyrla A, Shabalina E, Shamim M, Shan LY, Shank JT, Shao QT, Shapiro M, Shatalov PB, Shaver L, Shaw K, Sherman D, Sherwood P, Shibata A, Shichi H, Shimizu S, Shimojima M, Shin T, Shiyakova M, Shmeleva A, Shochet MJ, Short D, Shupe MA, Sicho P, Sidoti A, Siebel A, Siegert F, Sijacki D, Silbert O, Silva J, Silver Y, Silverstein D, Silverstein SB, Simak V, Simard O, Simic L, Simion S, Simmons B, Simonyan M, Sinervo P, Sinev NB, Sipica V, Siragusa G, Sircar A, Sisakyan AN, Sivoklokov SY, Sjölin J, Sjursen TB, Skinnari LA, Skottowe HP, Skovpen K, Skubic P, Skvorodnev N, Slater M, Slavicek T, Sliwa K, Sloper J, Smakhtin V, Smirnov SY, Smirnova LN, Smirnova O, Smith BC, Smith D, Smith KM, Smizanska M, Smolek K, Snesarev AA, Snow SW, Snow J, Snuverink J, Snyder S, Soares M, Sobie R, Sodomka J, Soffer A, Solans CA, Solar M, Solc J, Soldatov E, Soldevila U, Solfaroli Camillocci E, Solodkov AA, Solovyanov OV, Sondericker J, Soni N, Sopko V, Sopko B, Sosebee M, Soualah R, Soukharev A, Spagnolo S, Spanò F, Spighi R, Spigo G, Spila F, Spiwoks R, Spousta M, Spreitzer T, Spurlock B, St Denis RD, Stahl T, Stahlman J, Stamen R, Stanecka E, Stanek RW, Stanescu C, Stapnes S, Starchenko EA, Stark J, Staroba P, Starovoitov P, Staude A, Stavina P, Stavropoulos G, Steele G, Steinbach P, Steinberg P, Stekl I, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson K, Stewart GA, Stillings JA, Stockton MC, Stoerig K, Stoicea G, Stonjek S, Strachota P, Stradling AR, Straessner A, Strandberg J, Strandberg S, Strandlie A, Strang M, Strauss E, Strauss M, Strizenec P, Ströhmer R, Strom DM, Strong JA, Stroynowski R, Strube J, Stugu B, Stumer I, Stupak J, Sturm P, Soh DA, Su D, Subramania H, Succurro A, Sugaya Y, Sugimoto T, Suhr C, Suita K, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun X, Sundermann JE, Suruliz K, Sushkov S, Susinno G, Sutton MR, Suzuki Y, Suzuki Y, Svatos M, Sviridov YM, Swedish S, Sykora I, Sykora T, Szeless B, Sánchez J, Ta D, Tackmann K, Taffard A, Tafirout R, Taiblum N, Takahashi Y, Takai H, Takashima R, Takeda H, Takeshita T, Talby M, Talyshev A, Tamsett MC, Tanaka J, Tanaka R, Tanaka S, Tanaka S, Tanaka Y, Tani K, Tannoury N, Tappern GP, Tapprogge S, Tardif D, Tarem S, Tarrade F, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tatarkhanov M, Tayalati Y, Taylor C, Taylor FE, Taylor GN, Taylor W, Teinturier M, Teixeira Dias Castanheira M, Teixeira-Dias P, Temming KK, Ten Kate H, Teng PK, Terada S, Terashi K, Terron J, Terwort M, Testa M, Teuscher RJ, Thadome J, Therhaag J, Theveneaux-Pelzer T, Thioye M, Thoma S, Thomas JP, Thompson EN, Thompson PD, Thompson PD, Thompson AS, Thomson E, Thomson M, Thun RP, Tian F, Tic T, Tikhomirov VO, Tikhonov YA, Tipton P, Tique Aires Viegas FJ, Tisserant S, Tobias J, Toczek B, Todorov T, Todorova-Nova S, Toggerson B, Tojo J, Tokár S, Tokunaga K, Tokushuku K, Tollefson K, Tomoto M, Tompkins L, Toms K, Tong G, Tonoyan A, Topfel C, Topilin ND, Torchiani I, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Traynor D, Trefzger T, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Trinh TN, Tripiana MF, Trischuk W, Trivedi A, Trocmé B, Troncon C, Trottier-McDonald M, Trzebinski M, Trzupek A, Tsarouchas C, Tseng JCL, Tsiakiris M, Tsiareshka PV, Tsionou D, Tsipolitis G, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsung JW, Tsuno S, Tsybychev D, Tua A, Tudorache A, Tudorache V, Tuggle JM, Turala M, Turecek D, Turk Cakir I, Turlay E, Turra R, Tuts PM, Tykhonov A, Tylmad M, Tyndel M, Tyrvainen H, Tzanakos G, Uchida K, Ueda I, Ueno R, Ugland M, Uhlenbrock M, Uhrmacher M, Ukegawa F, Unal G, Underwood DG, Undrus A, Unel G, Unno Y, Urbaniec D, Urkovsky E, Usai G, Uslenghi M, Vacavant L, Vacek V, Vachon B, Vahsen S, Valenta J, Valente P, Valentinetti S, Valkar S, Valladolid Gallego E, Vallecorsa S, Valls Ferrer JA, van der Graaf H, van der Kraaij E, Van Der Leeuw R, van der Poel E, van der Ster D, van Eldik N, van Gemmeren P, van Kesteren Z, van Vulpen I, Vanadia M, Vandelli W, Vandoni G, Vaniachine A, Vankov P, Vannucci F, Varela Rodriguez F, Vari R, Varouchas D, Vartapetian A, Varvell KE, Vassilakopoulos VI, Vazeille F, Vegni G, Veillet JJ, Vellidis C, Veloso F, Veness R, Veneziano S, Ventura A, Ventura D, Venturi M, Venturi N, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinek E, Vinogradov VB, Virchaux M, Virzi J, Vitells O, Viti M, Vivarelli I, Vives Vaque F, Vlachos S, Vladoiu D, Vlasak M, Vlasov N, Vogel A, Vokac P, Volpi G, Volpi M, Volpini G, von der Schmitt H, von Loeben J, von Radziewski H, von Toerne E, Vorobel V, Vorobiev AP, Vorwerk V, Vos M, Voss R, Voss TT, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vu Anh T, Vuillermet R, Vukotic I, Wagner W, Wagner P, Wahlen H, Wakabayashi J, Walbersloh J, Walch S, Walder J, Walker R, Walkowiak W, Wall R, Waller P, Wang C, Wang H, Wang H, Wang J, Wang J, Wang JC, Wang R, Wang SM, Warburton A, Ward CP, Warsinsky M, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh AT, Waugh BM, Weber J, Weber M, Weber MS, Weber P, Weidberg AR, Weigell P, Weingarten J, Weiser C, Wellenstein H, Wells PS, Wen M, Wenaus T, Wendler S, Weng Z, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Werth M, Wessels M, Weydert C, Whalen K, Wheeler-Ellis SJ, Whitaker SP, White A, White MJ, Whitehead SR, Whiteson D, Whittington D, Wicke D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik LAM, Wijeratne PA, Wildauer A, Wildt MA, Wilhelm I, Wilkens HG, Will JZ, Williams E, Williams HH, Willis W, Willocq S, Wilson JA, Wilson MG, Wilson A, Wingerter-Seez I, Winkelmann S, Winklmeier F, Wittgen M, Wolter MW, Wolters H, Wong WC, Wooden G, Wosiek BK, Wotschack J, Woudstra MJ, Wraight K, Wright C, Wright M, Wrona B, Wu SL, Wu X, Wu Y, Wulf E, Wunstorf R, Wynne BM, Xella S, Xiao M, Xie S, Xie Y, Xu C, Xu D, Xu G, Yabsley B, Yacoob S, Yamada M, Yamaguchi H, Yamamoto A, Yamamoto K, Yamamoto S, Yamamura T, Yamanaka T, Yamaoka J, Yamazaki T, Yamazaki Y, Yan Z, Yang H, Yang UK, Yang Y, Yang Y, Yang Z, Yanush S, Yasu Y, Ybeles Smit GV, Ye J, Ye S, Yilmaz M, Yoosoofmiya R, Yorita K, Yoshida R, Young C, Youssef S, Yu D, Yu J, Yu J, Yuan L, Yurkewicz A, Zaets VG, Zaidan R, Zaitsev AM, Zajacova Z, Zalite YK, Zanello L, Zarzhitsky P, Zaytsev A, Zeitnitz C, Zeller M, Zeman M, Zemla A, Zendler C, Zenin O, Zeniš T, Zenonos Z, Zenz S, Zerwas D, Zevi Della Porta G, Zhan Z, Zhang D, Zhang H, Zhang J, Zhang X, Zhang Z, Zhao L, Zhao T, Zhao Z, Zhemchugov A, Zheng S, Zhong J, Zhou B, Zhou N, Zhou Y, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhuravlov V, Zieminska D, Zimmermann R, Zimmermann S, Zimmermann S, Ziolkowski M, Zitoun R, Zivković L, Zmouchko VV, Zobernig G, Zoccoli A, Zolnierowski Y, Zsenei A, Zur Nedden M, Zutshi V, Zwalinski L. Measurement of the ZZ production cross section and limits on anomalous neutral triple gauge couplings in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett 2012; 108:041804. [PMID: 22400826 DOI: 10.1103/physrevlett.108.041804] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2011] [Indexed: 05/31/2023]
Abstract
A measurement of the ZZ production cross section in proton-proton collisions at sqrt[s] = 7 TeV using data corresponding to an integrated luminosity of 1.02 fb(-1) recorded by the ATLAS experiment at the LHC is presented. Twelve events containing two Z boson candidates decaying to electrons and/or muons are observed, with an expected background of 0.3 ± 0.3(stat)(-0.3)(+0.4)(syst) events. The cross section measured in a phase-space region with good detector acceptance and for dilepton masses within the range 66 to 116 GeV is σ(ZZ → ℓ+ ℓ- ℓ+ ℓ-)(fid) = 19.4(-5.2)(+6.3)(stat)(-0.7)(+0.9)(syst) ± 0.7(lumi) fb. The resulting total cross section for on-shell ZZ production, σ(ZZ)(tot) = 8.5(-2.3)(+2.7)(stat)(-0.3)(+0.4)(syst) ± 0.3(lumi) pb, is consistent with the standard model expectation of 6.5(-0.2)(+0.3) pb calculated at the next-to-leading order in QCD. Limits on anomalous neutral triple gauge boson couplings are derived.
Collapse
Affiliation(s)
- G Aad
- Fakultät für Mathematik und Physik, Albert-Ludwigs-Universität, Freiburg i.Br., Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
|
46
|
Chen Q, Qu L, Tong G, Ni J. Simultaneous nutrients and carbon removal from low-strength domestic wastewater with an immobilised-microorganism biological aerated filter. Water Sci Technol 2011; 63:885-890. [PMID: 21411937 DOI: 10.2166/wst.2011.266] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
To improve the efficiency of low-strength domestic wastewater treatment, an immobilised-microorganism biological aerated filter (I-BAF) was established for simultaneous carbon, nitrogen and phosphorus removal. The I-BAF performance was systematically evaluated under continuous and intermittent aeration modes. At the optimal condition with an intermittent aeration control schedule of 2 h on/1 h off, the maximum removal rates of COD, NH(4)(+)-N, TN and P were 82.54%, 94.83%, 51.85% and 61.49%, respectively, and the corresponding averaged effluents could meet the first class standards of China. Further analysis of PCR-DGGE profile revealed that members of the gamma and alpha proteobacterium bacterial groups were probably responsible for the nitrogen and phosphorus removal. The I-BAF system showed excellent performance in carbon and nutrients removal, which provided a cost-effective solution for the treatment of low-strength domestic wastewater.
Collapse
Affiliation(s)
- Q Chen
- Department of Environmental Engineering, Peking University; The Key Laboratory of Water and Sediment Sciences, Ministry of Education, 5 Yiheyuan Road, Beijing 100871, China.
| | | | | | | |
Collapse
|
47
|
Sun Z, Cao F, Tong G, Sun D, Wang H. e0674 Insulin induces phosphorylation of Ndrg2 through activation of Akt in cardiomyocytes during transient ischaemia/reperfusion. Heart 2010. [DOI: 10.1136/hrt.2010.208967.674] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
48
|
Sun Z, Wang H, Tong G, Sun D, Cao F. e0178 Differential expression of N-Myc downstream regulated gene 2 (Ndrg2) in the rat heart after ischaemia/reperfusion injury. Heart 2010. [DOI: 10.1136/hrt.2010.208967.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
49
|
Wang N, Tong G, Pan H, Xu J, Ling F, Zhang X. e0367 Effect of treatment of hepatocyte growth-promoting factor on improvement of myocardial ischaemia and cardiopulmonary functional capacity during the exercise in patients with severe coronary heart disease. Heart 2010. [DOI: 10.1136/hrt.2010.208967.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
50
|
Tong G, Anderson L, Gray W, Macfie A. A clinical comparative study of the TruCCOMS and the Vigilance continuous cardiac output monitors in cardiac surgery. Anaesthesia 2003. [DOI: 10.1046/j.1365-2044.2003.03093_5.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|